Accepted Manuscript

Title: Lead structures for Applications in Photodynamic Therapy. 2. Synthetic studies for photo-triggered release systems of bioconjugate porphyrin photosensitizers

Authors: Mohd Bakri Bakar, Michael Oelgemöller, Mathias O. Senge

PII: S0040-4020(09)00895-3

DOI: [10.1016/j.tet.2009.06.037](https://doi.org/10.1016/j.tet.2009.06.037)

Reference: TET 19464

To appear in: *Tetrahedron*

Received Date: 18 March 2009

Revised Date: 15 May 2009

Accepted Date: 11 June 2009

Please cite this article as: Bakar MB, Oelgemöller M, Senge MO. Lead structures for Applications in Photodynamic Therapy. 2. Synthetic studies for photo-triggered release systems of bioconjugate porphyrin photosensitizers, *Tetrahedron* (2009), doi: 10.1016/j.tet.2009.06.037

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Graphical Abstract

To create your abstract, type over the instructions in the template box below.
Fonts or abstract dimensions should not be changed or altered.

Lead Structures for applications in photodynamic therapy. 2. Synthetic studies for photo-triggered release systems of bioconjugate porphyrin photosensitizers

Mohd Bakri Bakar, Michael Oelgemöller and Mathias O. Senge*

Pergamon

TETRAHEDRON

Lead structures for Applications in Photodynamic Therapy. 2. Synthetic studies for photo-triggered release systems of bioconjugate porphyrin photosensitizers

Mohd Bakri Bakar,^a Michael Oelgemöller^b and Mathias O. Senge^{a,c,*}

^a*School of Chemistry, SFI Tetrapyrrole Laboratory, Trinity College Dublin, Dublin 2, Ireland.*

^b*School of Pharmacy and Molecular Sciences, James Cook University, Townsville, Queensland 4811, Australia*

^c*Institute for Molecular Medicine, Medicinal Chemistry, Trinity Centre for Health Sciences, Trinity College Dublin, St. James's Hospital, Dublin 8, Ireland*

Abstract— Photodynamic therapy (PDT) selectivity and specificity can be improved by binding the photosensitizers to target receptors. One approach is to cross-link porphyrins to a biological target receptor via the photocleavable *o*-nitrobenzyl linker, where a controlled release of the porphyrin can be monitored upon irradiation. The synthetic pathways involved esterification of a porphyrin-carboxylic acid and a unit containing the *o*-nitrobenzyl alcohol moiety and the bioconjugate. Reactions of a model porphyrin and *o*-nitrobenzyl alcohol using the carbonyl activating carbodiimide reagent DCC gave a stable *N*-acyl urea porphyrin, whereas use of EDAC (1-ethyl-3-(3-dimethyl aminopropyl)carbodiimide hydrochloride) gave the desired compounds. Further studies were carried out on the attachment of carbohydrates (i.e. potentially receptor binding ligands) through such a linker to porphyrins. Preliminary irradiation experiments of such a compound show that upon UV irradiation (350nm) for 80 min, approximately 50% of the porphyrin was cleaved to release the carboxylic acid porphyrin photosensitizer indicating the utility of such systems as photosensitizers delivery systems. © 2009 Elsevier Science. All rights reserved

Keywords: porphyrins; carbodiimide; *o*-nitrobenzyl; photodynamic therapy; tetrapyrroles

1. Introduction

Photodynamic therapy (PDT) is a treatment modality based on photoactive substances of photosensitizers that localize preferentially in tumor cells. Irradiation of the target tissues with the appropriate wavelength of light activates the production of highly reactive oxygen and leads to a series of phototoxic reactions that cause selective death of tumor cells. Remarkable advancements have been made in recent decades to improve the efficiency of three PDT basic components: light, oxygen and photosensitizers; along with increased understanding of their biomedical and biophysical function.¹ Studies have been conducted to treat a variety of malignant and premalignant cancer conditions including head and neck cancer, lung cancer, mesothelioma, Barrett's esophagus, prostate and brain tumors.² The main advantage of PDT lies in it being a selective cancer treatment due to enrichment of the localized photosensitizers in the tissue and the directing of light to the affected tissue. The selectivity of PDT can be increased through targeted delivery of the photosensitizers to its site

of action. Thus, side-effects are minimized and the therapeutic window is widened through increasing the target/non-target tissue ratio. This can result in a reduction of the effective photosensitizer dose and its toxicity. In addition, the exact localization of a photosensitizer is important because the active singlet oxygen has a short life time of about 0.01 μ s with a range of action of about 0.01–0.02 μ m.³

Targeted delivery systems employing various carriers have been developed especially using hydrophobic photosensitizers.⁴ Common carriers can be divided into three classes: i) soluble carrier, such as monoclonal antibodies, emulsions or polymers;⁵ ii) particulate carriers of liposomes, nanoparticles or microspheres⁶ and iii) the target specific recognition⁷ of carbohydrates,⁸ lectins, oligonucleotides, epidermal growth factors, peptides, hormones, vitamins or lipoproteins. While the targeted photosensitizers delivery are capable of attaining site-specific delivery, a major concern is to control the release kinetics of the photosensitizers in a predictable manner and to deliver them at a pre-determined rate. One area of

interest is the development of photosensitizer release systems that can be triggered externally.⁹ For example, a photochemically triggered release system can be achieved through photocleavage of specific bonds in a pro-drug molecular system. This offers more control and specificity as the light beam can be turned on and off (temporal control) and light can be focused at particular sites (spatial control).

Our approach is to link porphyrin photosensitizers to ligand molecules and subsequently attempt a photo-release of the porphyrin photosensitizers in targeted tumor tissue. The construction of photocleavable porphyrin-conjugate systems will enhance the specific targeting of photosensitizers and localize their activation at defined effector places. In addition, tumor necrosis or induced apoptosis that contribute to cell death require light activation.¹⁰ Thus, photocleavable linkers would be most advantageous. We proposed earlier to utilize the photolabile spirobisdithianes and trithiane as such linker groups, however the strategy had its limits due to instability of the porphyrin systems towards photocleavage under ambient conditions.¹¹

Recently, photolabile *o*-nitrobenzyl linkers were utilized to design light-triggered anticancer pro-drugs which released the tegafur drug from porphyrins upon photolysis.¹² *o*-Nitrobenzyl linkers have advantages due to their compatibility with a variety of functional groups, ease of synthesis, stability under ambient light, clean cleavage and fast fragmentation upon photoirradiation.¹³ In the present work, we develop the necessary synthetic methodologies for the construction of labile systems for porphyrin photosensitizers based on the *o*-nitrobenzyl linker group and selected bioconjugates.

2. Results and discussion

2.1 Synthetic rational

Although various approaches to porphyrin functionalization have been established, esterification reactions have been mainly utilized in attempts to attach porphyrin moieties to bioconjugates via linker groups. Two synthetic pathways were chosen to synthesize the target compounds: i) esterification of porphyrin-carboxylic acids with *o*-nitrobenzyl alcohol containing systems and the appropriate bioconjugate and ii) the coupling of hydroxyl porphyrins with selected bioconjugates (Scheme 1).

These approaches require the presence of bioconjugates reactive towards the phenolic functional group. The latter method is developed through employing protecting group synthons, which later can be deprotected to obtain the active porphyrin, and provides convenient visual experimental monitoring due to associated color changes of

the porphyrins. Individual syntheses will be discussed for the specific target compounds.

Scheme 1. Synthetic rationale.

2.2 Starting materials- carboxylic acid porphyrins

A direct route to obtain carboxylic acid porphyrins is through hydrolysis of ester-type porphyrins. Several known methods are available. One of these is the use of palladium-catalysed Suzuki¹⁴ and Heck¹⁵ coupling reactions using halogenated porphyrin precursors. Hence, the initial step involved bromination¹⁶ at the meso- or β -position of several free base porphyrins (**1-6**) which were accessible through standard condensation¹⁷ or RLi-alkylation procedures.¹⁸ Consequently, Suzuki and Heck coupling reactions were carried out using methylester-boronic acid or -vinyl derivatives. These afforded a range of ester porphyrins in good yields (**7-15**) (Scheme 2).

Another method that enables the introduction of ester functional groups is to condense a mixture of pyrrole and the appropriately substituted benzaldehyde in a particular ratio.¹⁹ This condensation reaction leads to the synthesis of a tetrasubstituted compound (**16**) and ester porphyrin (**17**) (Scheme 2). Addition of zinc acetate as a metal template during the condensation process can facilitate the reaction, thus increasing the yield of the condensed products.²⁰ The free base porphyrin can be obtained subsequently under acidic conditions.

All of the ester porphyrins were further converted to functionalised carboxylic acids porphyrins via base-hydrolysis using NaOH-EtOH¹⁹ and afforded compounds **18-27** in high yields.

2.3 Esterification of porphyrins

The esterification of carboxylic acid porphyrins is often achieved using acylation²¹ or carbodiimide coupling techniques.²² However, the carbodiimide coupling offers a more feasible method as it requires simple and moderate conditions. We have investigated several preliminary esterification reactions between carboxylic acid porphyrins **7**, **9**, **28**,^{22c} **29**^{22d} and 2-nitrobenzylalcohol as the model linker using primarily *N,N'*-dicyclohexylcarbodiimide (DCC). However, the reactions tend to undergo rearrangement to form stable *N*-acylisourea species (**30-33**) instead of the reactive intermediates of *o*-

Scheme 2. Entry to carboxylic acid porphyrins.

acylisourea. A similar rearrangement was observed in crown ether macrocycles²³ and it has been suggested that this process occurs via a four-membered transition state (Scheme 3).

Scheme 3. Formation of *N*-acylisourea porphyrins.

A crystal structure of compound **30** clearly shows the *N*-acylisourea substitution pattern (Figure 1). Meanwhile, under optimized conditions (5 eq. DCC, 1 eq. DMAP, 5 eq.

nitrobenzylalcohol), we managed to obtain the respective nitrobenzyl-derivative of porphyrins (**34-35**) in moderate yields (Scheme 4). To overcome the problem of low yields it is necessary to stabilize the intermediate *o*-acylisourea using additive of *N*-hydroxysuccinimide (NHS) or 1-hydroxybenzotriazole (HOBt).²⁴ The additive acts as the intermediate nucleophile which converts the *o*-acylisourea to an activated ester containing nucleophile, thus preventing the rearrangement.

Figure 1. View of the molecular structure of **30** in the crystal. Hydrogen atoms have been omitted for clarity; thermal ellipsoids are drawn for 50% occupancy.

Further esterifications were carried out using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDAC) which has high solubility in water and organic solvents such as CH_2Cl_2 , THF, DMF and is easy to use. These reactions proceeded efficiently and gave the target compounds (**34-43**) in high yield (Scheme 5).

Scheme 4. Synthesis of nitrobenzyl porphyrins.

Scheme 5. Synthesis of nitrobenzyl porphyrins *via* EDAC-carbodiimide coupling reactions.

2.4 Porphyrin-linked carbohydrates

Porphyrins with carbohydrate moieties have been reported as efficient photosensitizer candidates for PDT.²⁵ Not only do they alter the amphiphilicity of the photosensitizers, but they also exhibit specific membrane interactions, thus resulting in specific targeting of tumor cells.²⁶ Therefore, a model compound of porphyrin-linker-bioconjugate was prepared by reaction of carboxylic acid porphyrin (**29**) with (3-hydroxymethyl-4-nitrophenyl)-2,3,4,6-tetra-*O*-acetyl- β -D-galactopyranoside²⁷ to yield the target compound **44** in 76% yield (Scheme 6).

Scheme 6. Synthesis of porphyrin-linked glucose derivatives.

2.5 Protecting group method

The synthesis of a nitrobenzyl analog containing an active phenolic group started with the protection of the phenolic group of 5-hydroxy-2-nitrobenzaldehyde using the acid-sensitive protecting group, 2-methoxyethoxymethyl (MEM) ether, giving **45**.²⁸ Further reduction with sodium borohydride at room temperature gave the respective nitrobenzyl alcohol **46** in quantitative yield. The esterification process with EDAC carbodiimide was employed using **18** to give **47**. Deprotection of the MEM group was carried out under neutral conditions to avoid adverse reactions from the acidic conditions. Heating of **47** using ethylene glycol²⁹ led to the formation of **48** due to nucleophilic attack of a hydroxyl group in ethylene glycol at the reactive benzylic carbon. The resulting product was esterified with the carboxylic acid porphyrin **49** and gave the bisporphyrin **50** in 93% yield (Scheme 7).

Scheme 7. Ethylene glycol deprotection method.

Scheme 8. Synthesis of porphyrin-linked folic acid.

Subsequently, we decided to use trifluoroacetic acid (TFA)³⁰ as a deprotection reagent for cases where the porphyrin core is required to be metallated to avoid unnecessary protonation. Porphyrin **47** was metallated with zinc acetate to give **51** which after further treatment with excess TFA, the reaction progressed smoothly to eliminate the MEM-group and demetallate the porphyrin moiety yielding **52** in 81% (Scheme 8). This compound opens an

entry for the attachment of diverse functional groups due to the presence of the phenolic group. However, an attempt to attach folic acid as a targeted bioconjugate³¹ did not proceed as planned. Therefore, further investigation will be carried out on the optimization of their reactivity and will be reported later.

2.6 Irradiation experiments

A solution of **44** was irradiated with long wavelength UV light (centered at 350 nm) and the photofragmentation reaction was monitored by HPLC. The conversion of **44** to **29** was followed as a function of time. It was observed that, upon irradiation for 80 min, approximately 50% of the porphyrin **29** was photocleaved. The cleavage product was identified as porphyrin **29** [MS (ES⁺): m/z = 995.6233 (M+H)⁺]. The mechanism of *o*-nitrobenzyl alcohol ester derivatives involves photoinduced intramolecular hydrogen abstraction and a redox rearrangement that form *o*-quinonoid intermediates, followed by releasing of the carboxylic acid and formation of nitrosobenzaldehyde.³² *o*-Nitroso benzaldehyde may further react to form secondary products via azobenzene-2,2'-dicarboxylic acid that acts as an internal filter, hence slowing the desired photoreaction.³³ Two approaches may be used to further increase its photoefficiency: (i) introduction of an additional *o*-nitro group to increase hydrogen abstraction of the excited nitro group and (ii) introduction of an α -substituent to the chromophore to enhance its efficiency for hydrogen abstraction. Both approaches require additional synthetic steps and are currently under investigation.

3. Conclusion

The results reported demonstrate that it is possible to synthesize compounds containing the required structural motifs for photo-cleavage. In addition, we could show the photolability of the target material. Although the deprotection is still not optimal, subsequent work will focus on improving the efficiency of the labile linker couplings and will target various bioconjugates to fulfill the potential of increased binding affinity to targeted cell receptors. Pending its success, this methodology will pave the way towards improved localization of photosensitizers in PDT and their controlled release.

4.0 Experimental

4.1 General Information

¹H NMR and ¹³C NMR spectra were recorded on a Bruker DPX 400 (400.13 MHz for ¹H NMR and 100.61 MHz for ¹³C NMR) and/or Bruker AV 600 (600.13 MHz for ¹H NMR and 150.90 MHz for ¹³C NMR) instrument. Chemical shifts are reported in ppm referenced to tetramethylsilane set at 0.00 ppm. High resolution mass spectrometry were measured on a Micromass/Waters Corp., USA liquid chromatography time-of-flight spectrometer equipped with an electrospray source. UV-vis measurements were performed on a Shimadzu MultiSpec-1501. Melting points were acquired on a Stuart SMP10 melting point apparatus and are uncorrected. Thin layer chromatography (TLC) was performed on silica gel 60F₂₅₄ (Merck) pre-coated aluminum sheets. Flash chromatography was carried out using Fluka Silica Gel 60 (230–400 mesh). Anhydrous THF distilled over sodium/benzophenone and dichloromethane dried over P₂O₅ were used. All

commercial chemicals were supplied by Aldrich and used without further purification.

4.2 Bromination of porphyrins

The porphyrin was dissolved in chloroform and a few drops of pyridine were added. The solution was then cooled to 0 °C. *N*-Bromosuccinimide (1.1 eq) was added and the mixture was stirred (TLC monitoring) followed by evaporation of the solvent *in vacuo* and purification via column chromatography.

4.2.1 5-Bromo-15-hexyl-10,20-diphenylporphyrin (1). A solution of 5-hexyl-10,20-diphenylporphyrin^{18d} (0.40 g, 0.73 mmol), pyridine (0.3 ml) and *N*-bromosuccinimide (0.14 g, 0.81 mmol) was dissolved in chloroform (150 ml) and stirred for 30 min. The title compound was purified by column chromatography on silica gel with *n*-hexane/dichloromethane (2:1, v/v) to yield **1** 0.46 g (0.29 mmol, 99%) as a purple solid: mp >310 °C; R_f=0.75 (SiO₂, CH₂Cl₂/C₆H₁₄, 1:1, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ = -2.72 (s, 2H, NH), 0.92 (t, J =7.0 Hz, 3H, -CH₃), 1.34-1.40 (m, 2H, -CH₂), 1.44-1.51 (m, 2H, -CH₂), 1.73-1.79 (m, 2H, -CH₂), 2.43-2.51 (m, 2H, -CH₂), 4.84 (t, J =8.1 Hz, 2H, -CH₂), 7.73-7.80 (m, 6H, phenyl-*H*), 8.16 (d, J =6.4 Hz, 4H, phenyl-*H*), 8.84 (s, 4H, β -*H*), 9.37 (d, J =4.7 Hz, 2H, β -*H*), 9.58 (d, J =4.7 Hz, 2H, β -*H*); ¹³C NMR (100 MHz, CDCl₃): δ = 13.74, 22.29, 29.79, 31.44, 35.08, 38.36, 101.47, 119.76, 121.25, 126.40, 127.39, 130.48, 131.54, 141.59 ppm; UV-vis (CH₂Cl₂): $\lambda_{\max}$ (log ϵ) = 420 (5.21), 520 (3.90), 554 (2.64), 598 (3.48), 654 (3.62); HRMS (ES⁺) [C₃₈H₃₃N₄Br]: calcd for [M+H]⁺ 625.1953, found 625.1967.

4.2.2 5-Bromo-15-hexyl-10,20-bis(3-methoxyphenyl) porphyrin (2). A solution of 5-hexyl-10,20-bis(3-methoxyphenyl) porphyrin^{18d} (0.50 g, 0.82 mmol), pyridine (0.3 ml) and *N*-bromosuccinimide (0.16 g, 0.91 mmol) was dissolved in chloroform (150 ml) and stirred for 30 min. The title compound was purified by column chromatography on silica gel with *n*-hexane/dichloromethane (1:1, v/v) to yield **2** 0.54 g (0.37 mmol, 95%) as a purple solid: mp =225 °C; R_f=0.36 (SiO₂, CH₂Cl₂/C₆H₁₄, 1:1, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ = -2.71 (s, 2H, NH), 0.91 (t, J =7.4 Hz, 3H, -CH₃), 1.35-1.40 (m, 2H, -CH₂), 1.46-1.50 (m, 2H, -CH₂), 1.73-1.78 (m, 2H, -CH₂), 2.44-2.52 (m, 2H, -CH₂), 3.99 (s, 6H, -OCH₃), 4.87 (t, J =7.7 Hz, 2H, -CH₂), 7.34 (dd, J_1 =1.8 Hz, J_2 =1.8 Hz, 2H, phenyl-*H*), 7.64 (t, J =8.1 Hz, 2H, phenyl-*H*), 7.75-7.78 (m, 4H, phenyl-*H*), 8.89 (d, J =4.4 Hz, 4H, β -*H*), 9.37 (d, J =4.8 Hz, 2H, β -*H*), 9.58 (d, J =4.8 Hz, 2H, β -*H*); ¹³C NMR (100 MHz, CDCl₃): δ = 22.73, 29.76, 30.25, 31.91, 35.52, 38.82, 55.54, 101.92, 113.63, 119.94, 120.50, 121.70, 127.53, 129.60, 143.36, 157.95 ppm; UV-vis (CH₂Cl₂): $\lambda_{\max}$ (log ϵ) = 421 (5.50), 520 (4.25), 554 (4.00), 598 (3.78), 654 (3.70); HRMS (ES⁺) [C₄₀H₃₇N₄O₂Br]: calcd for [M+H]⁺ 685.2178, found 685.2166.

4.2.3 2-Bromo-5,10,15,20-tetrakis(3,5-di-*tert*-butylphenyl)porphyrin (6). A solution of 5,10,15,20-tetrakis(3,5-di-*tert*-butylphenyl)porphyrin^{22d} (0.20 g, 0.19 mmol), pyridine (0.5 ml) and *N*-bromosuccinimide (0.04 g, 0.21 mmol) was dissolved in chloroform (100 ml) and stirred for 1 hour. The title compound was purified by column chromatography on silica gel with *n*-hexane/dichloromethane (1:1, v/v) to yield **6** (0.21 g, 0.24 mmol, 96%) as a purple solid: mp >310 °C; R_f =0.75 (SiO₂, CH₂Cl₂/C₆H₁₄, 1:1, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ = -2.79 (s, 2H, NH), 1.50 (s, 18H, -C(CH₃)₃), 1.52 (s, 54H, C(CH₃)₃), 7.78 (t, J =1.8 Hz, 3H, phenyl-*H*), 7.80 (t, J =1.8 Hz, 1H, phenyl-*H*), 7.92 (d, J =1.8 Hz, 1H, phenyl-*H*), 7.93 (d, J =1.8 Hz, 1H, phenyl-*H*), 8.03 (t, J =1.8 Hz, 1H, phenyl-*H*), 8.04 (d, J =1.8 Hz, 1H, phenyl-*H*), 8.06 (t, J =1.8 Hz, 3H, phenyl-*H*), 8.09 (d, J =1.8 Hz, 1H, phenyl-*H*), 8.82 (d, J =1.8 Hz, 1H, β -*H*), 8.89-8.94 (m, 5H, β -*H*), 8.94 (d, J =4.8 Hz, 1H, β -*H*); ¹³C NMR (100 MHz, CDCl₃): δ =29.73, 31.96, 35.06, 120.94, 121.35, 129.12, 129.73, 140.96, 141.38, 148.71, 148.90 ppm; UV-vis (CH₂Cl₂): $\lambda_{\max}$ (log ϵ)=423 (5.10), 520 (3.64), 554 (2.64), 598 (3.48), 654 (3.62); HRMS (ES⁺) [C₇₆H₉₄N₄Br]⁺: calcd for [M+H]⁺ 1141.6662, found. 1141.6544.

4.3 Synthesis of porphyrin ester

4.3.1 Method A: Suzuki cross coupling approach. To a stirred slurry of K₃PO₄ (40 eq.) in anhydrous THF were added bromoporphyrin (1 eq.), boronic acid (20 eq.), and Pd(PPh₃)₄ (0.2 eq.). The reaction was heated to reflux at 85 °C for 18 hours and shielded from light. The solvent was evaporated after completion and the residue was dissolved in CH₂Cl₂. This mixture was washed with saturated NaHCO₃, H₂O, and brine followed by drying over Na₂SO₄. The organic solvent was evaporated and the crude product was purified by column chromatography.

4.3.2 5-(4-Methoxycarbonylphenyl)-15-hexyl-10,20-diphenylporphyrin (7). K₃PO₄ (1.36 g, 6.39 mmol), 5-bromo-15-hexyl-10,20-diphenylporphyrin **1** (0.2 g, 0.32 mmol), 4-methoxy carbonylphenylboronic acid (0.58 g, 3.20 mmol) and Pd(PPh₃)₄ (0.04g, 0.03 mmol) were reacted in anhydrous THF (70 ml) following method A (4.3.1). The title compound was purified by column chromatography on silica gel with *n*-hexane/dichloromethane (1:1, v/v) and yielded **7** (0.29 g, 0.20 mmol, 82 %) as a purple solid: mp >310 °C; R_f =0.60 (SiO₂, EtOAc/*n*-hexane, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ = -2.67 (s, 2H, NH), 0.96 (t, J =7.0 Hz, 3H, -CH₃), 1.38-1.43 (m, 2H, -CH₂), 1.49-1.53 (m, 2H, -CH₂), 1.75-1.82 (m, 2H, -CH₂), 2.50-2.57 (m, 2H, -CH₂), 4.13 (s, 3H, -OCH₃), 4.91 (t, J =8.2 Hz, 2H, -CH₂), 7.75-7.81 (m, 6H, phenyl-*H*), 8.23 (d, J =7.6 Hz, 4H, phenyl-*H*), 8.32 (d, J =7.6 Hz, 2H, phenyl-*H*), 8.45 (d, J =7.6 Hz, 2H, phenyl-*H*), 8.79 (d, J =4.7 Hz, 2H, β -*H*), 8.85 (d, J =4.7 Hz, 2H, β -*H*), 8.93 (d, J =4.7 Hz, 2H, β -*H*), 9.44 (d, J =4.7 Hz, 2H, β -*H*); ¹³C NMR (100 MHz, CDCl₃): δ = 13.79, 22.34, 29.84, 31.50, 35.13, 38.49, 52.04, 117.34, 119.39, 120.83, 127.34, 127.56, 129.05, 134.20, 141.90,

146.62, 166.99 ppm; UV-vis (CH₂Cl₂): $\lambda_{\max}$ (log ϵ)= 419 (5.52), 517 (3.20), 551 (3.91), 593 (3.76), 649 (3.83); HRMS (ES⁺) [C₄₆H₄₁N₄O₂]: calcd for [M+H]⁺ 681.3230, found 681.3256.

4.3.3 5-(4-Methoxycarbonylphenyl)-15-hexyl-10,20-bis(3-methoxyphenyl)porphyrin (8). K₃PO₄ (3.10, 14.59 mmol), 5-bromo-15-hexyl-10,20-bis(3-methoxyphenyl)porphyrin **2** (0.50 g, 0.73 mmol), 4-methoxycarbonylphenylboronic acid (1.31 g, 7.29 mmol) and Pd(PPh₃)₄ (0.08 g, 0.07 mmol) were reacted in anhydrous THF (80 ml) following method A (4.3.1). The title compound was purified by column chromatography on silica gel with *n*-hexane/dichloromethane (1:2, v/v) and yielded **8** (0.41 g, 0.30 mmol, 63%) as a purple solid: mp =210 °C; R_f =0.36 (SiO₂, EtOAc/*n*-hexane, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ = -2.73 (s, 2H, NH), 0.92 (t, J =7.4 Hz, 3H, -CH₃), 1.36-1.42 (m, 2H, -CH₂), 1.47-1.54 (m, 2H, -CH₂), 1.76-1.84 (m, 2H, -CH₂), 2.50-2.58 (m, 2H, -CH₂), 3.99 (s, 6H, -OCH₃), 4.10 (s, 3H, -OCH₃), 4.98 (t, J =7.8 Hz, 2H, -CH₂), 7.37 (dd, J_1 =2.4 Hz, J_2 =2.0 Hz, 2H, phenyl-*H*), 7.64 (t, J =8.3 Hz, 2H, phenyl-*H*), 7.79 (t, J =7.8 Hz, 4H, phenyl-*H*), 8.27 (d, J =7.8 Hz, 2H, phenyl-*H*), 8.42 (d, J =8.3 Hz, 2H, phenyl-*H*), 8.73 (d, J =4.8 Hz, 2H, β -*H*), 8.86 (d, J =4.9 Hz, 2H, β -*H*), 8.96 (d, J =4.4 Hz, 2H, β -*H*), 9.46 (d, J =4.9 Hz, 2H, β -*H*); ¹³C NMR (100 MHz, CDCl₃): δ =14.20, 22.75, 30.29, 31.94, 35.60, 38.94, 52.45, 55.54, 113.55, 117.75, 119.53, 120.46, 121.28, 127.49, 127.63, 127.98, 129.48, 134.60, 143.64, 147.01, 157.93, 167.40 ppm; UV-vis (CH₂Cl₂): $\lambda_{\max}$ (log ϵ)= 419 (5.34), 516 (4.26), 551 (4.06), 593 (3.98), 650 (3.94); HRMS (ES⁺) [C₄₈H₄₅N₄O₄]: calcd for [M+H]⁺ 741.3441, found 741.3441.

4.3.4 5-(4-Methoxycarbonylphenyl)-10,20-diphenylporphyrin (9). K₃PO₄ (1.57g, 7.38 mmol), 5-bromo-10,20-diphenylporphyrin^{15a} (0.20 g, 0.37 mmol), 4-methoxy carbonylphenyl boronic acid (0.66 g, 3.69 mmol) and Pd(PPh₃)₄ (0.04 g, 0.04 mmol) were reacted in anhydrous THF (70 ml) according to method A (4.3.1). The title compound was purified by column chromatography on silica gel with *n*-hexane/dichloromethane (1:2, v/v) and yielded 0.22 g of **9** (0.13 mmol, 98%) as a purple solid: mp >310 °C; R_f =0.42 (SiO₂, CH₂Cl₂/C₆H₁₄, 2:1, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ = -3.02 (s, 2H, NH), 4.11 (s, 3H, -OCH₃), 7.77-7.80 (m, 6H, phenyl-*H*), 8.24 (dd, J_1 =2.3 Hz, J_2 =1.8 Hz, 4H, phenyl-*H*), 8.31 (d, J =8.2 Hz, 2H, phenyl-*H*), 8.42 (d, J =4.7 Hz, 2H, phenyl-*H*), 8.42 (d, J =4.7 Hz, 2H, β -*H*), 8.92 (d, J =4.7 Hz, 2H, β -*H*), 9.03 (d, J =4.7 Hz, 2H, β -*H*), 9.32 (d, J =4.7 Hz, 2H, β -*H*), 10.20 (s, 1H, meso-*H*); ¹³C NMR (100 MHz, CDCl₃): δ = 14.86, 52.02, 65.46, 104.75, 118.54, 119.44, 126.44, 127.37, 129.14, 130.62, 134.25, 141.19, 147.02, 166.93 ppm; UV-vis (CH₂Cl₂): $\lambda_{\max}$ (log ϵ)=413 (5.57), 509 (4.04), 542 (3.60), 584 (3.64) 638 (3.30); HRMS (ES⁺) [C₄₀H₂₉N₄O₂]: calcd for [M+H]⁺ 597.2291, found 597.2285.

4.3.5 5,15-Bis(4-methoxycarbonylphenyl)-10,20-diphenylporphyrin (10). K_3PO_4 (2.74 g, 12.90 mmol), 5,15-dibromo-10,20-diphenylporphyrin^{15a} (0.20 g, 0.32 mmol), 4-methoxycarbonylphenylboronic acid (1.16 g, 6.44 mmol) and $Pd(PPh_3)_4$ (0.07 g, 0.06 mmol) were reacted in anhydrous THF (70 ml) following procedure A (4.3.1). The crude mixture was purified by column chromatography on silica gel with *n*-hexane/dichloromethane (1:1, v/v) and yielded **10** (0.24 g, 94%) as a purple solid: mp >310 °C; $R_f=0.38$ (SiO_2 , CH_2Cl_2/C_6H_{14} , 1:1 v/v); ^1H NMR (400 MHz, $CDCl_3$, TMS): $\delta=-2.80$ (s, 2H, NH), 4.10 (s, 6H, -OCH₃), 7.64 (d, $J=8.2$ Hz, 6H, phenyl-*H*), 7.72-7.78 (m, 4H, phenyl-*H*), 8.09 (d, $J=8.8$ Hz, 2H, phenyl-*H*), 8.18 (d, $J=7.6$ Hz, 2H, phenyl-*H*), 8.31 (d, $J=8.2$ Hz, 2H, phenyl-*H*), 8.42 (d, $J=7.6$ Hz, 2H, phenyl-*H*), 8.80 (d, $J=4.7$ Hz, 4H, β -*H*), 8.86 (d, $J=4.7$ Hz, 4H, β -*H*); ^{13}C NMR (100 MHz, $CDCl_3$): $\delta=51.82, 118.51, 120.17, 126.33, 126.80, 127.49, 129.76, 134.13, 141.45, 143.88, 146.48, 166.37, 166.89$ ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ)= 419 (5.43), 515 (4.04), 550 (3.62), 592 (3.45), 648 (3.45); HRMS (ES+) [$C_{48}H_{34}N_4O_4$]: calcd for $[M+H]^+$ 731.2658, found 731.2620.

4.3.6 5-Hexyl-15-(3-methoxycarbonylphenyl)-10,20-diphenylporphyrin (11). K_3PO_4 (1.36 g, 6.39 mmol), 5-hexyl-15-bromo-10,20-diphenylporphyrin **1** (0.20 g, 0.32 mmol), 3-methoxycarbonylphenylboronic acid (0.58 g, 3.20 mmol), and $Pd(PPh_3)_4$ (0.03 g, 0.03 mmol) were reacted in anhydrous THF (70 ml) according to method A (4.3.1). The title compound was isolated by column chromatography on silica gel with *n*-hexane/dichloromethane (1:1, v/v) to give 0.18 g of **11** (0.12 mmol, 84%) as a purple solid: mp >310 °C; $R_f=0.77$ (SiO_2 , EtOAc/ C_6H_{14} , 1:3, v/v); ^1H NMR (400 MHz, $CDCl_3$, TMS): $\delta=-2.71$ (s, 2H, NH), 0.93 (t, $J=7.3$ Hz, 3H, -CH₃), 1.36-1.42 (m, 2H, -CH₂), 1.47-1.54 (m, 2H, -CH₂), 1.76-1.84 (m, 2H, -CH₂), 2.50-2.58 (m, 2H, -CH₂), 3.98 (s, 3H, -OCH₃), 4.98 (t, $J=8.0$ Hz, 2H, -CH₂), 7.75-7.80 (m, 6H, phenyl-*H*), 7.82 (t, $J=7.7$ Hz, 1H, phenyl-*H*), 8.21 (d, $J=6.2$ Hz, 4H, phenyl-*H*), 8.37 (d, $J=7.7$ Hz, 1H, phenyl-*H*), 8.46 (d, $J=7.7$ Hz, 1H, phenyl-*H*), 8.73 (d, $J=4.8$ Hz, 2H, β -*H*), 8.82 (d, $J=4.4$ Hz, 2H, β -*H*), 8.89 (s, 1H, phenyl-*H*), 8.92 (d, $J=4.8$ Hz, 2H, β -*H*), 9.47 (d, $J=4.8$ Hz, 2H, β -*H*); ^{13}C NMR (100 MHz, $CDCl_3$): $\delta=14.20, 22.75, 30.28, 31.93, 35.61, 38.93, 52.37, 117.77, 119.76, 121.14, 126.67, 126.93, 127.74, 128.89, 128.99, 134.52, 134.90, 138.54, 142.36, 142.47, 167.39$ ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ)=418 (5.14), 516 (4.08), 551 (3.93), 593 (3.88), 651 (3.89); HRMS (ES+) [$C_{46}H_{41}N_4O_2$]: calcd for $[M+H]^+$ 681.3230, found 681.3238.

4.3.7 5,15-Bis(3-methoxycarbonylphenyl)-10,20-bis(3,5-di-*tert*-butylphenyl)porphyrin (12). K_3PO_4 (1.01 g, 4.74 mmol), 5,15-dibromo-10,20-bis(3,5-di-*tert*-butylphenyl)porphyrin^{15b} (0.10 g, 0.12 mmol), 3-methoxycarbonylphenylboronic acid (0.43 g, 2.47 mmol) and $Pd(PPh_3)_4$ (0.03 g, 0.02 mmol) were heated to reflux in anhydrous THF (50 ml) following method A (4.3.1). The

title compound was isolated by column chromatography on silica gel with *n*-hexane/dichloromethane (1:2, v/v) to yield 0.09 g of **12** (0.09 mmol, 77 %) as a purple solid: mp =260 °C; $R_f=0.56$ (SiO_2 , CH_2Cl_2/C_6H_{14} , 1:1, v/v); ^1H NMR (400 MHz, $CDCl_3$, TMS): $\delta=-2.76$ (s, 2H, NH), 1.51 (s, 36H, - $(CH_3)_3$), 3.96 (s, 6H, -OCH₃), 7.79 (d, $J=8.8$ Hz, 2H, phenyl-*H*), 7.83 (d, $J=7.6$ Hz, 2H, phenyl-*H*), 8.06 (d, $J=1.8$ Hz, 4H, phenyl-*H*), 8.39 (d, $J=7.6$ Hz, 2H, phenyl-*H*), 8.45 (d, $J=7.6$ Hz, 2H, phenyl-*H*), 8.75 (d, $J=4.7$ Hz, 4H, phenyl-*H* and β -*H*), 8.89 (d, $J=4.6$ Hz, 6H, β -*H*); ^{13}C NMR (100 MHz, $CDCl_3$): $\delta=13.70, 22.26, 29.27, 31.39, 34.61, 51.91, 118.11, 120.68, 121.44, 126.39, 128.30, 128.56, 129.52, 134.33, 137.93, 140.50, 142.25, 148.37, 166.91$ ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ)= 421 (5.20), 517 (3.86), 553 (3.68), 595 (3.64), 654 (3.90); HRMS (ES+) [$C_{64}H_{66}N_4O_4$]: calcd for $[M+H]^+$ 955.5162, found 955.5205.

4.3.8 2-(4-Methoxycarbonylphenyl)-5,10,15,20-tetrakis-(3,5-di-*tert*-butylphenyl)porphyrin (13). K_3PO_4 (0.37 g, 1.75 mmol), 2-bromo-5,10,15,20-tetrakis(3,5-di-*tert*-butylphenyl)porphyrin **6** (0.10 g, 0.09 mmol), 4-methoxycarbonylphenylboronic acid (0.16 g, 0.88 mmol) and $Pd(PPh_3)_4$ (0.01 g, 0.01 mmol) were reacted in anhydrous THF (50 ml) according to method A (4.3.1). The product was purified by column chromatography on silica gel with *n*-hexane/dichloromethane (1:1, v/v) to yield 0.04 g of **7** (0.05 mmol, 52 %) as a purple solid: mp >310 °C; $R_f=0.57$ (SiO_2 , EtOAc/ C_6H_{14} , 1:5 v/v); ^1H NMR (400 MHz, $CDCl_3$, TMS): $\delta=-2.54$ (s, 2H, NH), 1.35 (s, 18H, - $C(CH_3)_3$), 1.53 (s, 54H, - $C(CH_3)_3$), 3.94 (s, 3H, -OCH₃), 7.24 (s, 1H, phenyl-*H*), 7.47 (d, $J=8.0$ Hz, 2H, phenyl-*H*), 7.80-7.82 (m, 7H, phenyl-*H*), 8.08 (dd, $J_f=1.8$ Hz, $J_t=1.4$ Hz, 4H, phenyl-*H*), 8.15 (d, $J=1.4$ Hz, 2H, phenyl-*H*), 8.71-8.75 (m, 2H, β -*H*), 8.87 (m, 5H, β -*H*); ^{13}C NMR (100 MHz, $CDCl_3$): $\delta=29.73, 31.94, 35.06, 52.02, 53.44, 121.01, 121.29, 122.19, 127.01, 128.55, 129.77, 130.66, 140.20, 141.42, 141.59, 148.64, 148.66, 167.15$ ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ)= 426 (5.43), 5.22 (4.00), 559 (3.56), 598 (3.08), 655 (3.51); HRMS (ES+) [$C_{84}H_{100}N_4O_2$]: calcd for $[M+H]^+$ 1197.7930, found. 1197.7880.

4.3.9 Method B: Heck coupling approach.

Bromoporphyrin (1 eq.), palladium acetate (0.2 eq.) di-*tert*-butylbiphenylphosphine (0.5 eq.) and K_2CO_3 (1.2 eq.) were added to a Schlenk tube and dried under vacuum. The vessel was filled with argon, followed by addition of dry DMF, dry toluene, and the vinyl reagent (50-fold excess). The mixture was then degassed via three freeze-pump-thaw cycles before the vessel was purged with argon again to ensure the reaction mixture was free of oxygen. The Schlenk flask was sealed and heated to 105 °C and the mixture was stirred for 15 hours. The progress of reaction was monitored by TLC and, upon completion, the mixture was diluted with toluene and washed with water. The organic layer was separated, dried over $MgSO_4$ and the residue was purified by column chromatography.

4.3.10 5-Hexyl-15-(2-methoxycarbonylethenyl)-10,20-diphenylporphyrin (14). Methyl acrylate (0.72 mL, 7.97 mmol) was added to the solution of 5-bromo-15-hexyl-10,20-diphenylporphyrin **1** (0.10 g, 0.16 mmol), palladium acetate (7.22 mg, 0.03 mmol), di-*tert*-butylbiphenylphosphine (24.59 mg, 0.08 mmol) and K_2CO_3 (27.33 mg, 0.20 mmol) in dry DMF (10 mL) and dry toluene (10 mL), followed by heating for 15 hours (see 4.3.9). The title compound was purified by column chromatography on silica gel with *n*-hexane/dichloromethane (1:2, v/v) and yielded 0.06 g (0.04 mmol, 60 %) of **14** as a purple solid: mp >310 °C; R_f =0.61 (SiO_2 , EtOAc/ C_6H_{14} , 1:3, v/v); ^1H NMR (400 MHz, $CDCl_3$, TMS): δ = -2.44 (s, 2H, NH), 0.90 (t, J =7.4 Hz, 3H, $-CH_3$), 1.33-1.39 (m, 2H, $-CH_2$), 1.46-1.49 (m, 2H, $-CH_2$), 1.73-1.80 (m, 2H, $-CH_2$), 2.45-2.53 (m, 2H, $-CH_2$), 4.04 (s, 3H, $-OCH_3$), 4.91 (t, J =7.7 Hz, 2H, $-CH_2$), 6.79 (d, J =15.8 Hz, 1H, $-CH=$), 7.73-7.80 (m, 6H, phenyl-*H*), 8.16 (d, J =6.2 Hz, 4H, phenyl-*H*), 8.83 (dd, J_1 =4.8 Hz, J_2 =4.8 Hz, 4H, β -*H*), 9.40 (t, J =4.4 Hz, 4H, β -*H*), 10.20 (d, J =15.8 Hz, 1H, $=CH$); ^{13}C NMR (100 MHz, $CDCl_3$): δ = 14.16, 22.71, 30.25, 31.89, 35.49, 38.81, 52.08, 111.19m 120.59, 122.73, 130.31, 142.18, 145.98, 166.86 ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ)= 426 (5.11), 526 (3.97), 565 (3.96), 600 (3.79), 654 (3.79); HRMS (ES+) [$C_{42}H_{39}N_4O_2$]: calcd for $[M+H]^+$ 631.3073, found 631.3062

4.3.11 5-Hexyl-15-(2-methoxycarbonylethenyl)-10,20-bis(3-methoxyphenyl)porphyrin (15). Methyl acrylate (0.66 mL, 7.26 mmol) was added to a solution of 5-bromo-15-hexyl-10,20-bis(3-methoxyphenyl)porphyrin **2** (0.10 g, 0.15 mmol), palladium acetate (6.59 mg, 0.03 mmol), di-*tert*-butylbiphenylphosphine (22.42 mg, 0.08 mmol) and K_2CO_3 (24.85 mg, 0.18 mmol) in dry DMF (10 mL) and dry toluene (10 mL), followed by heating for 15 hours (see 4.3.9). The mixture was purified by column chromatography on silica gel with *n*-hexane/dichloromethane (1:4, v/v) and yielded 0.06 g (0.04 mmol, 55%) of **15** as a purple solid: mp =275 °C; R_f =0.65 (SiO_2 , EtOAc/ C_6H_{14} , 1:3, v/v); ^1H NMR (400 MHz, $CDCl_3$, TMS): δ = -2.43 (s, 2H, NH), 0.96 (t, J =7.6 Hz, 3H, $-CH_3$), 1.34-1.40 (m, 2H, $-CH_2$), 1.44-1.50 (m, 2H, $-CH_2$), 1.73-1.81 (m, 2H, $-CH_2$), 2.45-2.53 (m, 2H, $-CH_2$), 3.99 (s, 6H, $-OCH_3$), 4.04 (s, 3H, $-OCH_3$), 4.90 (t, J =7.6 Hz, 2H, $-CH_2$), 6.80 (d, J =15.8 Hz, 1H, $-CH=$), 7.34 (dd, J_1 =2.3 Hz, J_2 =2.3 Hz, 2H, phenyl-*H*), 7.65 (t, J =8.2 Hz, 2H, phenyl-*H*), 7.77 (t, J =7.6 Hz, 4H, phenyl-*H*), 8.89 (dd, J_1 =4.7 Hz, J_2 =4.7 Hz, 4H, β -*H*), 9.39 (q, J =4.7 Hz, 4H, β -*H*), 10.21 (d, J =15.8 Hz, 1H, $=CH$); ^{13}C NMR (100 MHz, $CDCl_3$): δ =13.73, 22.28, 29.80, 31.45, 35.03, 38.37, 51.64, 55.09, 110.75, 113.17, 119.84, 119.98, 122.28, 129.85, 131.89, 143.04, 145.54, 157.50, 166.42 ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ)=427 (5.23), 526 (4.01), 566 (4.00), 599 (3.79), 657 (3.81); HRMS (ES+) [$C_{44}H_{42}N_4O_4$]: calcd for $[M+H]^+$ 691.3284, found 691.3293.

4.3.12 Method C: Condensation approach. To a mixture of aldehyde (4 eq.) and $Zn(OAc)_2$ (1 eq.) in propionic acid, pyrrole (4 eq.) was added at 100 °C over the course of 1 hours under vigorous stirring. The resulting dark solution was heated to reflux for further a 4h and then cooled to room temperature. The solvent was evaporated and the solid residue was filtered through silica gel and all product containing fractions were collected. The volume was reduced to 100 ml and pyridine and excess DDQ were added. The resulting mixture was heated at reflux for 1 hour. The solution was cooled to room temperature and evaporated to give a black-purple crude product followed by column chromatography on silica gel.

4.3.13 [5,10,15-Tris(3,5-di-*tert*-butylphenyl)-20-(4-methoxycarbonylphenyl)porphyrinato]zinc(II) (17). 4-Carboxymethylbenzaldehyde (0.25 g, 1.53 mmol), 3,5-di-*tert*-butylbenzaldehyde (1.00 g, 4.58 mmol), $Zn(OAc)_2$ (0.34 g, 1.53 mmol) and pyrrole (0.42 mL, 6.12 mmol) were reacted in propionic acid (30 mL) following method C (4.3.11). The solution volume was reduced to 100 ml and pyridine (0.5 mL) and DDQ (0.5 g) were added. The title compound was purified by column chromatography on silica gel with *n*-hexane/dichloromethane (1:1 v/v) gave a red solid of **17** as the second fraction (0.16 g, 0.17 mmol, 10%): mp >310 °C; R_f =0.44 (SiO_2 , EtOAc/ C_6H_{14} , 1:3, v/v); ^1H NMR (400 MHz, $CDCl_3$, TMS): δ =1.53 (s, 54H, $-C(CH_3)_3$), 4.03 (s, 3H, $-OCH_3$), 7.80 (d, J = 1.76 Hz, 3H, phenyl-*H*), 8.10 (s, 6H, phenyl-*H*), 8.31 (d, J =8.2 Hz, 2H, phenyl-*H*), 8.36 (d, J =8.2 Hz, 2H, phenyl-*H*), 8.89 (d, J =4.7 Hz, 2H, β -*H*), 9.02 (d, J =5.3 Hz, 6H, β -*H*); ^{13}C NMR (100 MHz, $CDCl_3$): δ =31.34, 34.62, 51.91, 118.69, 120.42, 122.22, 127.29, 128.71, 129.25, 130.83, 131.83, 131.98, 141.30, 147.59, 148.14, 149.03, 149.96, 150.16, 166.99 ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ)=423 (5.34), 549 (4.87), 589 (4.77); HRMS (ES+) [$C_{70}H_{78}O_2N_4Zn$]: calcd for $[M]$ 1070.5416, found 1070.5425. The first fraction contained [5,10,15,20-tetrakis(3,5-di-*tert*-butylphenyl)porphyrinato]zinc(II) **16**³⁴ (0.198 g, 0.22 mmol, 12 %) as a red solid.

4.4 Hydrolysis of porphyrin esters

4.4.1 General Method. A solution of porphyrin in THF, was mixed with ethanol and 2M NaOH and the suspension was heated to reflux (TLC monitor) before being cooled to room temperature. The mixture was acidified with aqueous HCl (1M) and extracted with chloroform. The organic extract was washed with saturated sodium bicarbonate aqueous solution and dried over anhydrous sodium sulfate. The solvent was then removed under reduced pressure before undergo further purification.

Spectroscopic data for porphyrin **21** in accordance with previous literature.^{19b}

4.4.2 5-(4-Carboxyphenyl)-15-hexyl-10,20-diphenylporphyrin (18). 5-(4-Methoxycarbonylphenyl)-15-hexyl-10,20-diphenylporphyrin **7** (0.10 g, 0.15 mmol) was

heated to reflux in THF (20 mL), ethanol (25 mL) and 2M NaOH (50 mL) for 2 hours. Filtration through a plug of silica gel eluting with (CH₂Cl₂: EtOAc = 5:1) followed by evaporation of the solvent gave a purple solid of **18** (0.09 g, 0.06 mmol, 93%): mp >310 °C; R_f=0.24 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ= -2.67 (s, 2H, NH), 0.96 (t, *J*=7.0 Hz, 3H, -CH₃), 1.20-1.24 (m, 2H, -CH₂), 1.58-1.64 (m, 2H, -CH₂), 1.74-1.80 (m, 2H, -CH₂), 2.51-2.56 (m, 2H, -CH₂), 5.17 (t, *J*=8.2 Hz, 2H, -CH₂), 7.85-80.00 (m, 6H, phenyl-*H*), 8.08 (d, *J*=7.6 Hz, 4H, phenyl-*H*), 8.28 (d, *J*=7.6 Hz, 2H, phenyl-*H*), 8.40 (d, *J*=7.6 Hz, 4H, phenyl-*H*), 8.52 (d, *J*=4.7 Hz, 2H, β-*H*), 8.87 (d, *J*=4.7 Hz, 2H, β-*H*), 8.96 (d, *J*=4.7 Hz, 2H, β-*H*), 9.21 (d, *J*=4.7 Hz, 2H, β-*H*); ¹³C NMR (100 MHz, CDCl₃): δ=13.74, 22.29, 27.75, 29.03, 29.75, 31.46, 34.03, 34.85, 38.29, 99.86, 118.41, 119.68, 122.80, 125.13, 126.13, 127.30, 128.41, 130.92, 134.09, 135.11, 141.02, 143.86, 148.96 ppm; UV-vis (CH₂Cl₂): λ_{max} (log ε)=419 (5.26), 518 (4.60), 552 (4.54), 594 (4.49), 647 (4.47); HRMS (ES+) [C₄₅H₃₉N₄O₂]: calcd for [M+H]⁺ 667.3073, found. 667.3068.

4.4.3 5-(4-Carboxyphenyl)-15-hexyl-10,20-bis(3-methoxyphenyl)porphyrin (19).

5-(4-Methoxycarbonylphenyl)-15-hexyl-10,20-bis(3-methoxyphenyl)porphyrin **8** (0.18 g, 0.24 mmol) was heated to reflux in THF (15 mL), ethanol (30 mL) and 2M NaOH (30 mL) for 5 hours. Filtration through a plug of silica gel eluting with (CH₂Cl₂: EtOAc = 5:1) and evaporation of the solvent gave a purple solid of **19** (0.16 g, 0.11 mmol, 93%): mp >310 °C; R_f=0.13 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ= -3.07 (s, 2H, NH), 0.95 (t, *J*=7.4 Hz, 3H, -CH₃), 1.34-1.38 (m, 2H, -CH₂), 1.40-1.46 (m, 2H, -CH₂), 1.70-1.76 (m, 2H, -CH₂), 2.38-2.47 (m, 2H, -CH₂), 3.98 (s, 6H, -OCH₃), 5.00 (t, *J*=7.8 Hz, 2H, -CH₂), 7.37 (d, *J*=7.8 Hz, 2H, phenyl-*H*), 7.72 (t, *J*=8.2 Hz, 2H, phenyl-*H*), 7.85 (t, *J*=7.8 Hz, 4H, phenyl-*H*), 8.14 (d, *J*= 7.8 Hz, 2H, phenyl-*H*), 8.47 (d, *J*= 8.3 Hz, 2H, phenyl-*H*), 8.73 (d, *J*=4.8 Hz, 2H, β-*H*), 8.86 (d, *J*=4.9 Hz, 2H, β-*H*), 8.90 (d, *J*=4.4 Hz, 2H, β-*H*), 9.12 (d, *J*=4.9 Hz, 2H, β-*H*); ¹³C NMR (100 MHz, CDCl₃): δ=14.22, 21.29, 22.76, 25.66, 29.52, 30.42, 31.90, 34.33, 38.80, 54.47, 68.08, 112.45, 118.58, 119.61, 125.62, 126.27, 126.57, 128.13, 134.69, 135.87, 142.77, 144.64, 151.62, 156.87, 176.39 ppm; UV-vis (CH₂Cl₂): λ_{max} (log ε)= 420 (5.27), 516 (4.35), 551 (4.13), 593 (4.08), 648 (4.08); HRMS (ES+) [C₄₇H₄₃N₄O₄]: calcd for [M+H]⁺ 727.3284, found. 727.3256.

4.4.4 5-(4-Carboxyphenyl)-10,20-diphenylporphyrin (20).

5-(4-Methoxycarbonylphenyl)-10,20-diphenylporphyrin **9** (0.15 g, 0.09 mmol) was heated to reflux in THF, ethanol (40mL) and 2M NaOH (95 ml) for 11 hours. Filtration through a plug of silica gel eluting with (CH₂Cl₂: EtOAc = 5:1) and evaporation of the solvent followed by recrystallization from MeOH/H₂O gave a purple solid of **20** (0.11 g, 0.06 mmol, 77%): mp >310 °C; R_f=0.29 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃,

TMS): δ= -3.30 (s, 2H, NH), 7.54-7.72 (m, 6H, phenyl-*H*), 8.02-8.04 (m, 6H, phenyl-*H*), 8.17 (d, *J*=7.5 Hz, 2H, phenyl-*H*), 8.68 (d, *J*=14.0 Hz, 4H, β-*H*), 8.82 (s, 2H, β-*H*), 9.17 (s, 2H, β-*H*), 10.05 (s, 1H, meso-*H*); ¹³C NMR (100 MHz, CDCl₃): δ= 30.73, 31.44, 32.04, 97.03, 107.36, 109.48, 113.21, 118.70, 120.88, 122.17, 122.44, 129.86, 130.22, 133.87, 136.62, 144.02, 147.48, 175.96 ppm; UV-vis (CH₂Cl₂): λ_{max} (log ε)= 413 (5.27), 509 (4.23), 542 (4.04), 582 (4.04), 636 (3.95); HRMS (ES+) [C₃₉H₂₇N₄O₂]: calcd for [M+H]⁺ 583.2134, found. 583.2134.

4.4.5 5-(3-Carboxyphenyl)-15-hexyl-10,20-diphenylporphyrin (22).

5-(3-Methoxycarbonylphenyl)-15-hexyl-10,20-diphenylporphyrin **11** (0.14 g, 0.21 mmol) was heated to reflux in THF (20 mL), ethanol (30 mL) and 2M NaOH (30 mL) for 2 hours. Filtration through a plug of silica gel eluting with (CH₂Cl₂: EtOAc = 5:1) followed by evaporation of the solvent gave a purple solid of **22** (0.13 g, 0.09 mmol, 94%): mp >310 °C; R_f=0.24 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ= -2.78 (s, 2H, NH), 0.88 (t, *J*=7.3 Hz, 3H, -CH₃), 1.31-1.34 (m, 2H, -CH₂), 1.42-1.48 (m, 2H, -CH₂), 1.73-1.79 (m, 2H, -CH₂), 2.45-2.53 (m, 2H, -CH₂), 4.96 (t, *J*=7.8 Hz, 2H, -CH₂), 7.67-7.72 (m, 6H, phenyl-*H*), 7.76 (t, *J*=7.7 Hz, 1H, phenyl-*H*), 8.13 (d, *J*=6.8 Hz, 4H, phenyl-*H*), 8.27 (d, *J*=6.8 Hz, 1H, phenyl-*H*), 8.49 (d, *J*= 7.8 Hz, 1H, phenyl-*H*), 8.72 (d, *J*=4.9 Hz, 4H, β-*H*), 8.85 (d, *J*=4.9 Hz, 2H, β-*H*), 8.93 (s, 1H, phenyl-*H*), 9.43 (d, *J*=4.9 Hz, 2H, β-*H*); ¹³C NMR (100 MHz, CDCl₃): δ=13.67, 20.72, 22.24, 27.72, 31.43, 33.84, 35.11, 38.42, 65.93, 67.48, 117.88, 119.15, 120.44, 124.41, 125.04, 126.14, 127.19, 128.65, 134.01, 134.97, 137.58, 143.92, 144.32, 151.09, 168.86 ppm; UV-vis (CH₂Cl₂): λ_{max} (log ε)= 418 (5.31), 517 (4.30), 550 (4.18), 595 (4.00), 651 (4.00); HRMS (ES+) [C₄₅H₃₉N₄O₂]: calcd for [M+H]⁺ 667.3073, found. 667.3072.

4.4.6 5,15-Bis(3-carboxyphenyl)-10,20-bis(3,5-di-*tert*-butylphenyl)porphyrin (23).

5,15-Bis(3-methoxycarbonylphenyl)-10,20-bis(3,5-di-*tert*-butylphenyl)porphyrin **12** (0.02 g, 0.02 mmol) was heated to reflux in THF (10 mL), ethanol (20 mL) and 2M NaOH (20 mL) for 5 hours. Filtration through a plug of silica gel eluting with (CH₂Cl₂: EtOAc = 5:1) followed by evaporation of the solvent gave a purple solid of **23** (16.5 mg, 0.02 mmol, 89%): mp > 310 °C; R_f=0.23 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ= -2.83 (s, 2H, NH), 1.50 (s, 36H, -(CH₃)₃), 7.29 (s, 2H, phenyl-*H*), 7.90-7.95 (m, 6H, phenyl-*H*), 8.04 (t, *J*=4.0 Hz, 2H, phenyl-*H*), 8.44 (dd, *J*₁=1.5 Hz, *J*₂=3.4 Hz, 4H, phenyl-*H*), 9.07 (d, *J*=4.7 Hz, 4H, β-*H*), 9.37 (d, *J*=4.6 Hz, 4H, β-*H*); ¹³C NMR (100 MHz, CDCl₃): δ= 31.30, 32.11, 44.65, 119.20, 123.74, 124.41, 126.65, 127.58, 128.40, 129.64, 132.20, 140.66, 142.23, 149.45, 165.85 ppm; UV-vis (CH₂Cl₂): λ_{max} (log ε)= 408 (5.11), 503 (4.61), 573 (4.58), 598 (4.54), 652 (4.54); HRMS (ES+) [C₆₂H₆₃N₄O₄]: calcd for [M+H]⁺ 927.4849, found 927.4872.

4.4.7 2-(4-Carboxyphenyl)-5,10,15,20-tetrakis(3,5-di-*tert*-butylphenyl)porphyrin (24). 2-(4-Methoxycarbonylphenyl)-5,10,15,20-tetrakis(3,5-di-*tert*-butylphenyl)-porphyrin **13** (0.03 g, 0.03 mmol) was heated to reflux in THF (5 mL), ethanol (10 mL) and 2M NaOH (10 mL) for 5 hours. Filtration through a plug of silica gel eluting with CH₂Cl₂ followed by evaporation of the solvent gave a purple solid of **24** (0.03 g, 0.03 mmol, 82%): mp >310 °C; R_f=0.28 (SiO₂, EtOAc/C₆H₁₄, 1:5, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ= -2.77 (s, 2H, NH), 1.22 (s, 48H, -C(CH₃)₃), 1.22 (s, 24H, -C(CH₃)₃), 7.52 (s, 2H, phenyl-*H*), 7.79 (s, 1H, phenyl-*H*), 7.89 (s, 5H, phenyl-*H*), 8.06 (s, 2H, phenyl-*H*), 8.42 (br. s, 2H, phenyl-*H*), 8.73 (d, *J*= 1.8 Hz, 2H, phenyl-*H*), 8.81 (d, *J*= 1.8 Hz, 2H, phenyl-*H*), 8.85 (d, *J*=4.8 Hz, 5H, β-*H*), 8.95 (s, 2H, β-*H*); ¹³C NMR (100 MHz, CDCl₃): δ=29.73, 31.94, 35.06, 52.02, 53.46, 121.01, 121.50, 122.19, 127.01, 128.55, 129.77, 130.65, 141.59, 148.67, 167.15 ppm; UV-vis (CH₂Cl₂): λ_{max} (log ε)= 426 (5.25), 523 (4.20), 560 (4.04), 598 (3.90), 653 (3.95); HRMS (ES+) [C₈₃H₉₈N₄O₂]: calcd for [M+H]⁺ 1183.7768, found. 1183.7727.

4.4.8 5-(2-Carboxyethenyl)-15-hexyl-10,20-diphenylporphyrin (25). 5-Hexyl-15-(2-methoxycarbonylphenyl)-10,20-diphenylporphyrin **14** (0.03 g, 0.02 mmol) was heated to reflux in THF (5 mL), ethanol (10 mL) and 2M NaOH (10 mL) for 3 hours. Filtration through a plug of silica gel eluting with (CH₂Cl₂: EtOAc = 5:1) followed by evaporation of the solvent gave a purple solid of **25** (0.03 g, 0.02 mmol, 93%): mp >310 °C; R_f=0.19 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ= -2.40 (s, 2H, NH), 0.93 (t, *J*=7.4 Hz, 3H, -CH₃), 1.35-1.38 (m, 2H, -CH₂), 1.40-1.55 (m, 2H, -CH₂), 1.70-1.79 (m, 2H, -CH₂), 2.14-2.50 (m, 2H, -CH₂), 5.09 (t, *J*=7.7 Hz, 2H, -CH₂), 6.83 (d, *J*=15.8 Hz, 1H, -CH=), 7.90-7.94 (m, 6H, phenyl-*H*), 8.26 (d, *J*=6.2 Hz, 4H, phenyl-*H*), 8.80 (d, *J*=4.7 Hz, 4H, β-*H*), 8.96 (d, *J*=5.3 Hz, 2H, β-*H*), 9.71 (t, *J*=4.4 Hz, 2H, β-*H*), 10.16 (d, *J*=15.8 Hz, 1H, =CH); ¹³C NMR (100 MHz, CDCl₃): δ=13.65, 22.20, 24.19, 29.21, 29.73, 31.33, 38.28, 55.02, 94.26, 106.61, 126.31, 127.60, 127.99, 128.58, 133.66, 141.27 ppm; UV-vis (CH₂Cl₂): λ_{max} (log ε)= 426 (5.26), 527 (3.78), 569 (3.86), 601 (3.30), 654 (3.48); HRMS (ES+) [C₄₁H₃₇N₄O₂]: calcd for [M+H]⁺ 617.2917, found. 617.2901.

4.4.9 5-(2-Carboxyethenyl)-15-hexyl-10,20-bis(3-methoxyphenyl)porphyrin (26). 5-Hexyl-15-(2-methoxycarbonylphenyl)-10,20-bis(3-methoxyphenyl)porphyrin **15** (0.06 g, 0.08 mmol) was heated to reflux in THF (5 mL), ethanol (10 mL) and 2M NaOH (10 mL) for 3 hours. Filtration through a plug of silica gel eluting with (CH₂Cl₂: EtOAc = 5:1) followed by evaporation of the solvent gave a purple solid of **26** (0.05 g, 0.03 mmol, 88%): mp =197 °C; R_f=0.19 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ= -2.43 (s, 2H, NH), 0.98 (t, *J*=7.6 Hz, 3H, -CH₃), 1.27-1.33 (m, 2H, -CH₂), 1.55-1.60 (m, 2H, -CH₂), 1.84-1.88 (m, 2H, -CH₂), 2.52-2.58 (m, 2H, -CH₂), 4.06 (s, 6H, -OCH₃), 5.12 (t, *J*=7.6 Hz, 2H,

-CH₂), 6.85 (d, *J*=15.8 Hz, 1H, -CH=), 7.48 (d, *J*=8.2 Hz, 2H, phenyl-*H*), 7.75 (t, *J*=8.2 Hz, 2H, phenyl-*H*), 7.84 (t, *J*=7.6 Hz, 4H, phenyl-*H*), 8.94 (d, *J*=13.4 Hz, 4H, β-*H*), 9.72 (d, *J*=4.7 Hz, 2H, β-*H*), 9.91 (d, *J*=4.7 Hz, 2H, β-*H*), 10.20 (d, *J*=15.8 Hz, 1H, =CH); ¹³C NMR (100 MHz, CDCl₃): δ=14.17, 21.25, 22.72, 25.63, 29.47, 31.80, 34.28, 38.67, 54.39, 55.56, 67.99, 112.28, 118.90, 119.78, 120.45, 126.77, 128.30, 135.81, 142.64, 143.25, 151.57, 156.81 ppm; UV-vis (CH₂Cl₂): λ_{max} (log ε)= 427 (5.33), 525 (4.32), 571 (4.32), 599 (4.18), 654 (4.15); HRMS (ES+) [C₄₃H₄₁N₄O₄]: calcd for [M+H]⁺ 677.3128, found. 677.3121.

4.4.10 [5-(4-Carboxyphenyl)-10,15,20-tris(3,5-di-*tert*-butylphenyl)porphyrinato]zinc(II) (27). [5,10,15-Tris(3,5-di-*tert*-butylphenyl)-20(4-methoxycarbonylphenyl)porphyrinato]zinc(II) **17** (0.12 g, 0.13 mmol) was heated to reflux in THF (5 mL), ethanol (20 mL) and 2M NaOH (20 mL) for 5 hours. Filtration through a plug of silica gel eluting with CH₂Cl₂ followed by evaporation of the solvent yielded a purple solid of **27** (0.10 g, 0.10 mmol, 82%): mp >310 °C; R_f=0.32 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ=1.40 (s, 36H, -C(CH₃)₃), 1.52 (s, 18H, -C(CH₃)₃), 7.68 (s, 1H, phenyl-*H*), 7.78 (s, 2H, phenyl-*H*), 8.01 (s, 4H, phenyl-*H*), 8.08 (s, 2H, phenyl-*H*), 8.44 (s, 2H, phenyl-*H*), 8.97 (s, 2H, phenyl-*H*), 8.97 (s, 8H, β-*H*); ¹³C NMR (100 MHz, CDCl₃): δ=31.23, 34.49, 120.22, 122.07, 128.14, 129.18, 131.08, 131.70, 134.06, 141.30, 147.98, 149.23, 149.87, 149.92 ppm; UV-vis (CH₂Cl₂): λ_{max} (log ε)= 423 (5.11), 551 (4.86), 589 (4.78); HRMS (ES+) [C₆₉H₇₇N₄O₂Zn]: calcd for [M+H]⁺ 1056.526, found. 1056.530.

4.5 Esterification of carboxylic acid porphyrins

4.5.1 Method A: DCC carbodiimide reagent approach.

To a solution of porphyrin, *N,N*-dicyclohexylcarbodiimide (DCC) and dimethylamino-pyridine (DMAP) in dry THF, a solution of 2-nitrobenzylalcohol in THF was added at room temperature. The mixture was heated to reflux for 18 hours and diluted with THF before being extracted with a solution of aq. NH₄Cl. The organic solvent was washed with brine and dried over Na₂SO₄ followed by evaporation of the solvent under reduced pressure and purification by column chromatography.

4.5.2 5-(4-Dicyclohexylureacarbonylphenyl)-15-hexyl-10,20-diphenylporphyrin (30).

5-(4-Carboxyphenyl)-15-hexyl-10,20-diphenylporphyrin **18** (0.03 g, 0.04 mmol), DCC (9.3 mg, 0.04 mmol), DMAP (4.84 mg, 0.04 mmol) and 2-nitrobenzylalcohol (34.4 mg, 0.03 mmol) were heated to reflux for 18 h in THF (10 mL) according to method A (4.5.1). Purification on silica gel (*n*-hexane/dichloromethane = 1:2, v/v) yielded the intermediate product of title compound as a purple solid (11.7 mg, 0.01 mmol, 30%): mp >310 °C; R_f=0.37 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ= -2.71 (s, 2H, NH), 0.89-0.93 (m, 2H, -CH₂), 0.96

(t, J = 14.6 Hz, 3H, -CH₃), 1.16-1.20 (m, 2H, -CH₂), 1.38-1.45 (m, 4H, -CH₂), 1.51-1.56 (m, 2H, -CH₂), 1.61-1.65 (m, 2H, -CH₂), 1.73-1.78 (m, 4H, -CH₂), 1.84 (t, J = 15.2 Hz, 2H, -CH₂), 1.92-1.94 (m, 4H, -CH₂), 2.05-2.07 (m, 2H, -CH₂), 2.16-2.25 (m, 2H, -CH₂), 2.54-2.61 (m, 2H, -CH₂), 3.71-3.78 (m, 1H, -N-CH), 4.38-4.45 (m, 1H, -CON-CH), 5.04 (t, J = 8.2 Hz, 2H, -CH₂), 6.31 (d, J = 7.0 Hz, 1H, -NH), 7.81 (t, J = 7.6 Hz, 6H, phenyl-*H*), 7.98 (d, J = 7.6 Hz, 2H, phenyl-*H*), 8.24 (d, 4H, J = 6.4 Hz, phenyl-*H*), 8.28 (d, J = 7.6 Hz, 2H, phenyl-*H*), 8.76 (d, J = 4.7 Hz, 2H, β -*H*), 8.84 (d, J = 4.7 Hz, 2H, β -*H*), 8.95 (d, J = 4.7 Hz, 2H, β -*H*), 9.52 (d, J = 4.7 Hz, 2H, β -*H*); ¹³C NMR (100 MHz, CDCl₃): δ = 13.73, 22.29, 24.19, 25.98, 30.47, 31.47, 35.16, 38.50, 49.49, 57.07, 62.05, 119.35, 120.82, 124.86, 126.23, 127.31, 134.04, 141.85, 144.44, 154.05 ppm; UV-vis (CH₂Cl₂): $\lambda_{\max}$ (log ϵ) = 419 (5.31), 517 (3.94), 551 (3.64), 594 (4.51), 653 (3.75); HRMS (ES⁺) [C₅₈H₆₁N₆O₂]: calcd for [M+H]⁺ 873.4856 found 873.4874.

4.5.3 5-(4-Dicyclohexylurea-carbonylphenyl)-10,20-diphenylporphyrin (31). 5-(4-Carboxyphenyl)-10,20-diphenylporphyrin **19** (0.05 g, 0.09 mmol), DCC (17.7 mg, 0.09 mmol), DMAP (9.25 mg, 0.09 mmol) and 2-nitrobenzylalcohol (65.6 mg, 0.43 mmol) were heated to reflux for 18 h in THF (10 mL) according to method A (4.5.1). Purification on silica gel (*n*-hexane/dichloromethane = 1:2, v/v) yielded the intermediate product of **31** as a purple solid (26.4 mg, 0.02 mmol, 39%): mp >310 °C; R_f = 0.32 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ = -3.01 (s, 2H, NH), 0.87-0.92 (m, 2H, -CH₂), 1.13-1.21 (m, 2H, -CH₂), 1.37-1.47 (m, 4H, -CH₂), 1.59-1.67 (m, 2H, -CH₂), 1.74-1.77 (m, 2H, -CH₂), 1.89-1.95 (m, 4H, -CH₂), 2.04-2.07 (m, 2H, -CH₂), 2.15-2.24 (m, 2H, -CH₂), 3.71-3.75 (m, 1H, -N-CH), 4.39-4.45 (m, 1H, -CON-CH), 6.33 (d, J = 7.0 Hz, 1H, -NH), 7.79 (t, J = 7.6 Hz, 6H, phenyl-*H*), 7.97 (d, J = 7.6 Hz, 2H, phenyl-*H*), 8.24 (d, 4H, J = 6.4 Hz, phenyl-*H*), 8.28 (d, J = 7.6 Hz, 2H, phenyl-*H*), 8.82 (d, J = 4.7 Hz, 2H, β -*H*), 8.92 (d, J = 4.7 Hz, 2H, β -*H*), 9.02 (d, J = 4.7 Hz, 2H, β -*H*), 9.31 (d, J = 4.7 Hz, 2H, β -*H*), 10.19 (s, 1H, meso-*H*); ¹³C NMR (100 MHz, CDCl₃): δ = 24.48, 26.01, 29.31, 30.51, 32.25, 57.07, 104.77, 118.46, 119.45, 124.77, 126.47, 127.40, 134.27, 135.93, 141.20, 144.92, 154.08, 167.36, 170.77 ppm; UV-vis (CH₂Cl₂): $\lambda_{\max}$ (log ϵ) = 413 (5.29), 509 (3.87), 542 (3.04), 586 (3.11), 654 (2.90); HRMS (ES⁺) [C₅₂H₄₉N₆O₂]: calcd for [M+H]⁺ 789.3917 found 789.3934.

4.5.4 5-(4-(*o*-Nitrobenzylcarboxy)phenyl)-10,15,20-triphenylporphyrin (34). 5-(4-Carboxyphenyl)-10,15,20-triphenylporphyrin^{21c} (0.02 g, 0.03 mmol), DCC (34.88 mg, 0.15 mmol), DMAP (18.15 mg, 0.15 mmol) and 2-nitrobenzylalcohol (0.17 g, 0.15 mmol) were heated to reflux for 18 h in THF (10 mL) according to method A (4.5.1). The crude product was purified on silica gel (*n*-hexane/dichloromethane = 2:1, v/v) and the first fraction corresponds to the title compound of 5-(4-(*o*-nitrobenzylcarboxy)phenyl)-10,15,20-triphenylporphyrin **34** as a

purple solid (6.6 mg, 0.01 mmol, 27%). >310°C; R_f = 0.69 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ = -2.80 (s, 2H, NH), 5.95 (s, 2H, -OCH₂), 7.55 (t, J = 8.2 Hz, 1H, phenyl-*H*), 7.72 (d, J = 2.8 Hz, 1H, phenyl-*H*), 7.76 (t, J = 7.3 Hz, 9H, phenyl-*H*), 7.86 (d, J = 7.0 Hz, 1H, phenyl-*H*), 8.18 (s, 1H, phenyl-*H*), 8.19-8.21 (m, 6H, phenyl-*H*), 8.32 (d, J = 8.2 Hz, 2H, phenyl-*H*), 8.47 (d, J = 8.2 Hz, 2H, phenyl-*H*), 8.79 (d, J = 4.7 Hz, 2H, β -*H*), 8.84 (t, J = 5.2 Hz, 6H, β -*H*); ¹³C NMR (100 MHz, CDCl₃): δ = 13.70, 22.27, 29.27, 31.49, 63.25, 117.84, 119.97, 124.79, 126.29, 127.67, 131.93, 133.49, 134.11, 141.57, 147.17, 147.28, 165.73 ppm; UV-vis (CH₂Cl₂): $\lambda_{\max}$ (log ϵ) = 419 (5.15), 516 (4.59), 551 (4.51), 597 (4.48), 649 (4.54); HRMS (ES⁺) [C₅₂H₃₆N₅O₄]: calcd for [M+H]⁺ 794.2767, found 794.2781. The second fraction corresponds to the intermediate product of 5-(4-dicyclohexylurea-carbonylphenyl)-10,15,20-triphenyl porphyrin **32** as a purple solid (13.7 mg, 0.12 mmol, 52%): mp >310 °C; R_f = 0.52 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ = -2.83 (s, 2H, NH), 0.82-0.88 (m, 2H, -CH₂), 1.13-1.19 (m, 2H, -CH₂), 1.34-1.43 (m, 4H, -CH₂), 1.58-1.64 (m, 2H, -CH₂), 1.67-1.75 (m, 2H, -CH₂), 1.83-1.90 (m, 4H, -CH₂), 1.98-2.03 (m, 2H, -CH₂), 2.11-2.18 (m, 2H, -CH₂), 3.67-3.75 (m, 1H, -N-CH), 4.34-4.40 (m, 1H, CON-CH), 6.30 (d, 1H, -NH), 7.75 (d, J = 6.4 Hz, 9H, phenyl-*H*), 7.95 (d, J = 7.0 Hz, 2H, phenyl-*H*), 8.20 (d, 6H, J = 7.0 Hz, phenyl-*H*), 8.26 (d, J = 7.0 Hz, 2H, phenyl-*H*), 8.77 (s, 2H, β -*H*), 8.83 (s, 6H, β -*H*); ¹³C NMR (100 MHz, CDCl₃): δ = 29.27, 32.21, 62.09, 124.57, 126.30, 127.37, 128.04, 129.51, 133.69, 134.12, 141.57, 167.54 ppm; UV-vis (CH₂Cl₂): $\lambda_{\max}$ (log ϵ) = 418 (5.16), 515 (3.95), 550 (3.75), 0.022 (3.64), 0.026 (3.72); HRMS (ES⁺) [C₅₈H₅₃N₆O₂]: calcd for [M+H]⁺ 865.423, found 865.4211. Alternatively compound **34** was prepared via method B (4.5.6). 5-(4-Carboxyphenyl)-10,15,20-triphenylporphyrin **28** (0.02 g, 0.03 mmol), EDAC (5.83 mg, 0.03 mmol), DMAP (3.71 mg, 0.03 mmol) and 2-nitrobenzylalcohol (4.66 mg, 0.03 mmol) were stirred for 18 h in DCM (10 mL) at rt. Purification on silica gel (*n*-hexane/dichloromethane = 1:2, v/v) yielded **34** as a purple solid (17.6 mg, 0.01 mmol, 73%).

4.5.5 5,10,15-Tris(3,5-di-*tert*-butylphenyl)-20-(4-(*o*-nitrobenzyl-carboxy)phenyl)porphyrin (35). 5-(4-Carboxyphenyl)-10,15,20-tris(3,5-di-*tert*-butylphenyl)porphyrin^{21d} (0.02 g, 0.02 mmol), DCC (23.25 mg, 0.10 mmol), DMAP (12.10 mg, 0.10 mmol) and 2-nitrobenzylalcohol (0.11 g, 0.10 mmol) were heated to reflux for 18 h in THF (10 mL) according to method A (4.5.1). The crude product was purified on silica gel (*n*-hexane/dichloromethane = 2:1, v/v) and the first fraction corresponds to the title compound **35** as purple solid (8.6 mg, 0.01 mmol 38%): mp >310 °C; R_f = 0.48 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ = -2.71 (s, 2H, NH), 1.52 (s, 54H, -C(CH₃)₃), 5.96 (s, 2H, -OCH₂), 7.55 (t, J = 7.6 Hz, 1H, phenyl-*H*), 7.73 (d, J = 8.1 Hz, 1H, phenyl-*H*), 7.76 (s, 3H, phenyl-*H*), 7.86 (d, J = 7.9 Hz, 1H, phenyl-*H*), 8.08 (t, J = 7.9 Hz, 6H, phenyl-*H*),

8.20 (d, $J=8.1$ Hz, 1H, phenyl-*H*), 8.35 (d, $J=8.2$ Hz, 2H, phenyl-*H*), 8.48 (d, $J=8.2$ Hz, 2H, phenyl-*H*), 8.79 (d, $J=4.7$ Hz, 2H, β -*H*), 8.91 (s, 6H, β -*H*); ^{13}C NMR (100 MHz, CDCl_3): $\delta=13.72$, 22.28, 29.28, 31.30, 34.61, 63.23, 120.62, 121.22, 127.63, 128.66, 129.40, 134.25, 140.68, 148.32, 165.79 ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ)= 422 (5.16), 518 (4.66), 571 (4.65), 599 (4.61), 651 (4.65); HRMS (ES+) [$\text{C}_{76}\text{H}_{84}\text{N}_5\text{O}_4$]: calcd for $[\text{M}+\text{H}]^+$ 1130.6523, found 1130.6526. The second fraction corresponds to the intermediate product of 5-(4-di-cyclohexylurea-carbonyl phenyl)-10,15,20-tris(3,5-di-*tert*-butylphenyl) porphyrin **33** as a purple solid (10.3 mg, 0.01 mmol, 43%): mp >310 °C; $R_f=0.46$ (SiO_2 , EtOAc/ C_6H_{14} , 1:3, v/v); ^1H NMR (400 MHz, CDCl_3 , TMS): $\delta=-2.69$ (s, 2H, *NH*), 0.87-0.95 (m, 2H, $-\text{CH}_2$), 1.15-1.20 (m, 2H, $-\text{CH}_2$), 1.41-1.46 (m, 4H, $-\text{CH}_2$), 1.52 (s, 54H, $-\text{C}(\text{CH}_3)_3$), 1.79-1.82 (m, 2H, $-\text{CH}_2$), 1.94-1.98 (m, 4H, $-\text{CH}_2$), 2.05-2.08 (m, 2H, $-\text{CH}_2$), 2.15-2.24 (m, 2H, $-\text{CH}_2$), 2.52-2.58 (m, 2H, $-\text{CH}_2$), 3.74 (d, $J=7.6$ Hz, 1H, $-\text{N}-\text{CH}$), 4.45 (t, $J=11.7$ Hz, 1H, $\text{CON}-\text{CH}$), 6.23 (d, $J=6.4$ Hz, 1H, $-\text{NH}$), 7.85 (d, $J=1.8$ Hz, 3H, phenyl-*H*), 8.00 (d, $J=7.0$ Hz, 2H, phenyl-*H*), 8.12 (dd, $J_1=1.8$ Hz, $J_2=1.8$ Hz, 6H, phenyl-*H*), 8.34 (d, $J=7.0$ Hz, 2H, phenyl-*H*), 8.82 (d, 2H, β -*H*), 8.95 (s, 6H, β -*H*); ^{13}C NMR (100 MHz, CDCl_3): $\delta=24.30$, 25.96, 29.27, 31.30, 32.28, 34.61, 62.10, 117.43, 120.58, 121.18, 124.57, 128.04, 129.47, 133.69, 136.33, 140.67, 148.32, 154.08, 165.73 ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ)= 421 (5.33), 518 (3.64), 554 (3.20), 596 (2.60), 655 (3.64); HRMS (ES+) [$\text{C}_{82}\text{H}_{101}\text{N}_6\text{O}_2$]: calcd for $[\text{M}+\text{H}]^+$ 1201.799 found 1201.804. Alternatively compound **35** was prepared via method B (4.5.6). 5-(4-Carboxyphenyl)-10,15,20-tris(3,5-di-*tert*-butylphenyl)porphyrin^{21d} (0.02 g, 0.02 mmol), EDAC (7.66 mg, 0.04 mmol), DMAP (4.88 mg, 0.04 mmol) and 2-nitrobenzylalcohol (12.4 mg, 0.08 mmol) were stirred for 18 h in DCM (10 mL) according to method B (4.5.6). Purification on silica gel (*n*-hexane/dichloromethane = 1:2, v/v) yielded **35** as a purple solid (19.5 mg, 0.02 mmol, 86%).

4.5.6 Method B: EDAC carbodiimide reagent approach.

To a solution of porphyrin (1 eq.), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDAC) (2 eq.) and dimethylaminopyridine, (DMAP) (2 eq.) in dry DCM, a solution of 2-nitrobenzylalcohol (4 eq.) in DCM were added at rt. The mixture was stirred at rt for 18 hours. Upon completion, the solution was diluted with DCM and extracted with a solution of aqueous NH_4Cl . The mixture was washed with brine and dried over Na_2SO_4 , followed by evaporation of the solvent to give the crude product and purification by column chromatography.

4.5.7 5-Hexyl-15-(4-(*o*-nitrobenzylcarboxy)phenyl)-10,20-diphenylporphyrin (36).

5-Hexyl-15-(4-carboxyphenyl)-10,20-diphenylporphyrin **18** (0.02 g, 0.03 mmol), EDAC (11.5 mg, 0.06 mmol), DMAP (7.31 mg, 0.06 mmol) and 2-nitrobenzylalcohol (18.6 mg, 0.12 mmol) were stirred for 18 h in DCM (10 mL) at rt according to method B (4.5.6). Purification on silica gel (*n*-

hexane/dichloromethane = 1:2, v/v) yielded **36** as a purple solid (13.0 mg, 0.01 mmol, 81%): mp >310 °C; $R_f=0.75$ (SiO_2 , EtOAc/ C_6H_{14} , 1:3, v/v); ^1H NMR (400 MHz, CDCl_3 , TMS): $\delta=-2.75$ (s, 2H, *NH*), 0.92 (t, $J=7.3$ Hz, 3H, $-\text{CH}_3$), 1.39-1.41 (m, 2H, $-\text{CH}_2$), 1.45-1.47 (m, 2H, $-\text{CH}_2$), 1.74-1.82 (m, 2H, $-\text{CH}_2$), 2.50-2.65 (m, 2H, $-\text{CH}_2$), 5.01 (t, $J=8.0$ Hz, 2H, $-\text{CH}_2$), 5.95 (s, 2H, $-\text{OCH}_2$), 7.50 (t, $J=8.2$ Hz, 1H, phenyl-*H*), 7.56 (d, $J=2.8$ Hz, 1H, phenyl-*H*), 7.72-7.76 (m, $J=7.3$ Hz, 6H, phenyl-*H*), 7.86 (d, $J=7.0$ Hz, 1H, phenyl-*H*), 8.18 (dd, $J_1=1.8$ Hz, $J_2=1.1$ Hz, 4H, phenyl-*H*), 8.24 (s, 1H, phenyl-*H*), 8.29 (d, $J=8.4$ Hz, 2H, phenyl-*H*), 8.45 (d, $J=8.4$ Hz, 2H, phenyl-*H*), 8.72 (d, $J=4.8$ Hz, 2H, β -*H*), 8.79 (d, $J=4.8$ Hz, 2H, β -*H*), 8.89 (d, $J=4.8$ Hz, 2H, β -*H*), 9.48 (d, $J=4.8$ Hz, 2H, β -*H*); ^{13}C NMR (100 MHz, CDCl_3): $\delta=14.14$, 22.71, 29.38, 30.05, 30.28, 31.46, 31.95, 34.96, 63.68, 124.18, 124.40, 125.25, 126.66, 127.76, 127.97, 128.85, 128.93, 129.16, 130.93, 133.94, 134.74, 142.28, 151.22, 151.85 ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ)= 419 (5.48), 516 (4.48), 551 (4.37), 592 (4.33), 651 (4.29); HRMS (ES+) [$\text{C}_{52}\text{H}_{44}\text{N}_5\text{O}_4$]: calcd for $[\text{M}+\text{H}]^+$ 802.3393, found 802.3401.

4.5.8 5-Hexyl-10,20-bis(3-methoxyphenyl)-15-(4-(*o*-nitrobenzylcarboxy)phenyl)-porphyrin (37).

5-(3-carboxyphenyl)-15-hexyl-10,20-bis(3-methoxyphenyl)porphyrin **19** (0.02 g, 0.03 mmol), EDAC (10.54 mg, 0.06 mmol), DMAP (6.71 mg, 0.06 mmol) and 2-nitrobenzylalcohol (17.06 mg, 0.11 mmol) were stirred for 18 h in DCM (10 mL) at rt according to method B (4.5.6). Purification on silica gel (*n*-hexane/dichloromethane = 1:1, v/v) yielded **37** as a purple solid (19.6 mg, 0.02 mmol, 83%): mp $=227$ °C; $R_f=0.38$ (SiO_2 , EtOAc/ C_6H_{14} , 1:3, v/v); ^1H NMR (400 MHz, CDCl_3 , TMS): $\delta=-2.84$ (s, 2H, *NH*), 0.92 (t, $J=7.3$ Hz, 3H, $-\text{CH}_3$), 1.36-1.39 (m, 2H, $-\text{CH}_2$), 1.49-1.52 (m, 2H, $-\text{CH}_2$), 1.57-1.62 (m, 2H, $-\text{CH}_2$), 1.77-1.85 (m, 2H, $-\text{CH}_2$), 3.98 (s, 6H, $-\text{OCH}_3$), 4.99 (t, $J=7.7$ Hz, 2H, $-\text{CH}_2$), 5.93 (s, 2H, $-\text{OCH}_2$), 7.33 (d, $J=8.1$ Hz, 2H, phenyl-*H*), 7.53 (t, $J=7.7$ Hz, 1H, phenyl-*H*), 7.58 (t, $J=8.0$ Hz, 2H, phenyl-*H*), 7.72 (t, $J=7.36$ Hz, 1H, phenyl-*H*), 7.78 (t, $J=7.7$ Hz, 4H, phenyl-*H*), 7.83 (d, $J=7.7$ Hz, 1H, phenyl-*H*), 8.17 (d, $J=8.1$ Hz, 1H, phenyl-*H*), 8.29 (d, $J=8.4$ Hz, 2H, phenyl-*H*), 8.46 (d, $J=8.4$ Hz, 2H, phenyl-*H*), 8.73 (d, $J=4.8$ Hz, 2H, β -*H*), 8.85 (d, $J=4.8$ Hz, 2H, β -*H*), 8.95 (d, $J=4.8$ Hz, 2H, β -*H*), 9.46 (d, $J=4.8$ Hz, 2H, β -*H*); ^{13}C NMR (100 MHz, CDCl_3): $\delta=14.18$, 22.74, 29.72, 30.33, 31.93, 35.62, 38.96, 55.55, 62.42, 63.69, 113.56, 117.52, 119.58, 120.50, 121.37, 124.96, 127.51, 128.41, 128.94, 129.81, 132.37, 133.94, 134.76, 136.82, 143.54, 147.50, 157.94, 166.24 ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ)= 419 (5.31), 514 (4.26), 550 (4.15), 578 (4.30), 654 (4.45); HRMS (ES+) [$\text{C}_{54}\text{H}_{47}\text{N}_5\text{O}_6$]: calcd for $[\text{M}+\text{H}]^+$ 862.3605, found 862.3610.

4.5.9 [5,10,15-Tris(3,5-di-*tert*-butylphenyl)-20-(4-(*o*-nitrobenzylcarboxy)phenyl)porphyrinato]zinc(II) (38).

[5-(4-Carboxyphenyl)-10,15,20-tris(3,5-di-*tert*-butylphenyl)porphyrinato]zinc(II) **27** (0.02 g, 0.02 mmol), EDAC (7.21 mg, 0.04 mmol), DMAP (4.59 mg, 0.04

mmol) and 2-nitrobenzylalcohol (11.5 mg, 0.08 mmol) were stirred for 18 h in DCM (10 mL) at rt according to method B (4.5.6). Purification on silica gel (*n*-hexane/dichloromethane = 1:2, v/v) yielded **38** as a purple solid (19.4 mg, 0.02 mmol, 81%); mp >310 °C; R_f =0.65 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ=1.52 (s, 54H, -C(CH₃)₃), 5.91 (s, 2H, -OCH₂), 7.52 (t, *J*=8.4 Hz, 1H, phenyl-*H*), 7.73 (t, *J*=8.4 Hz, 1H, phenyl-*H*), 7.78–7.80 (m, 3H, phenyl-*H*), 7.83 (d, *J*=8.0 Hz, 1H, phenyl-*H*), 8.08–8.09 (m, 6H, phenyl-*H*), 8.18 (dd, *J*₁=1.8 Hz, *J*₂=1.8 Hz, 1H, phenyl-*H*), 8.35 (d, *J*=8.2 Hz, 2H, phenyl-*H*), 8.48 (d, *J*=8.2 Hz, 2H, phenyl-*H*), 8.89 (d, *J*=4.7 Hz, 2H, β-*H*), 8.91 (s, 6H, β-*H*); ¹³C NMR (100 MHz, CDCl₃): δ=22.71, 29.72, 31.77, 35.07, 63.60, 118.90, 120.87, 122.70, 125.21, 127.93, 128.90, 129.61, 132.43, 133.91, 134.57, 141.73, 148.61, 149.41, 150.41, 166.26 ppm; UV-vis (CH₂Cl₂): λ_{max} (log ε)= 423 (5.29), 549 (4.65), 650 (4.54); HRMS (ES+) [C₇₆H₈₁N₅O₄Zn]: calcd for [M] 1191.5580, found 1191.5614.

4.5.10 5-Hexyl-15-(3'-(*o*-nitrobenzylcarboxy)phenyl)-10,20-diphenylporphyrin (39). 5-(3-Carboxyphenyl)-15-hexyl-10,20-diphenylporphyrin **22** (0.02 g, 0.03 mmol), EDAC (11.5 mg, 0.06 mmol), DMAP (7.31 mg, 0.06 mmol) and 2-nitrobenzylalcohol (18.6 mg, 0.12 mmol) were stirred for 18 h in DCM (10 mL) according to method B (4.5.6). Purification on silica gel (*n*-hexane/dichloromethane = 1:1, v/v) yielded **39** as a purple solid (16.8 mg, 0.01 mmol, 70%); mp >310 °C; R_f =0.60 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ=−2.74 (s, 2H, NH), 0.92 (t, *J*=7.3 Hz, 3H, -CH₃), 1.35–1.49 (m, 2H, -CH₂), 1.46–1.50 (m, 2H, -CH₂), 1.78–1.84 (m, 2H, -CH₂), 2.50–2.58 (m, 2H, -CH₂), 5.00 (t, *J*=8.0 Hz, 2H, -CH₂), 5.83 (s, 2H, -OCH₂), 7.38 (t, *J*=8.4 Hz, 1H, phenyl-*H*), 7.52 (t, *J*=7.7 Hz, 1H, phenyl-*H*), 7.65 (d, *J*=7.7 Hz, 1H, phenyl-*H*), 7.76 (m, 6H, phenyl-*H*), 7.85 (t, *J*=7.7 Hz, 1H, phenyl-*H*), 8.06 (d, *J*=8.4 Hz, 1H, phenyl-*H*), 8.19 (d, *J*=6.2 Hz, 4H, phenyl-*H*), 8.41 (d, *J*=7.7 Hz, 1H, phenyl-*H*), 8.49 (d, *J*=7.7 Hz, 1H, phenyl-*H*), 8.72 (d, *J*=4.8 Hz, 2H, β-*H*), 8.80 (d, *J*=4.8 Hz, 2H, β-*H*), 8.91 (t, *J*=2.2 Hz, 3H, phenyl-*H* and β-*H*), 9.48 (d, *J*=4.8 Hz, 2H, β-*H*); ¹³C NMR (100 MHz, CDCl₃): δ=14.18, 22.74, 29.45, 29.74, 30.28, 31.93, 35.63, 38.95, 63.60, 117.46, 119.80, 121.24, 125.08, 126.67, 127.13, 127.75, 128.30, 129.19, 133.84, 134.90, 138.91, 142.30, 147.44, 166.17 ppm; UV-vis (CH₂Cl₂): λ_{max} (log ε)= 418 (5.48), 516 (4.47), 551 (4.36), 594 (4.32), 650 (4.33); HRMS (ES+) [C₅₂H₄₄N₅O₄]: calcd for [M+H]⁺ 802.3393, found 802.3380.

4.5.11 5,15-Bis(3,5-di-*tert*-butylphenyl)-10,20-bis(3-(*o*-nitrobenzylcarboxy)phenyl)porphyrin (40). 5,15-Bis(3,5-di-*tert*-butylphenyl)-10,20-bis(3-carboxyphenyl)porphyrin **23** (0.01 g, 0.01 mmol), EDAC (10.91 mg, 0.11 mmol), DMAP (6.94 mg, 0.11 mmol) and 2-nitrobenzylalcohol (17.63 mg, 0.23 mmol) were stirred for 18 h in DCM (10 mL) according to method B (4.5.6). Purification on silica gel (*n*-hexane/dichloromethane = 1:1, v/v) yielded the title compound **40** as a purple solid (8.30

mg, 0.01 mmol, 58%); mp >310 °C; R_f =0.48 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ=−2.76 (s, 2H, NH), 1.51 (s, 36H, -C(CH₃)₃), 5.85 (s, 4H, -OCH₂), 7.42 (t, *J*=7.3 Hz, 2H, phenyl-*H*), 7.57 (t, *J*=7.7 Hz, 2H, phenyl-*H*), 7.69 (d, *J*=7.7 Hz, 2H, phenyl-*H*), 7.79 (s, 2H, phenyl-*H*), 7.87 (t, *J*=7.7 Hz, 2H, phenyl-*H*), 8.08 (d, *J*=9.6 Hz, 6H, phenyl-*H*), 8.44 (d, *J*=8.1 Hz, 2H, phenyl-*H*), 8.51 (d, *J*=8.51 Hz, 2H, phenyl-*H*), 8.77 (s, 2H, phenyl-*H*), 8.78 (s, 2H, β-*H*), 8.90 (d, *J*=4.76 Hz, 4H, β-*H*), 8.94 (s, 2H, β-*H*); ¹³C NMR (100 MHz, CDCl₃): δ=27.85, 29.71, 31.73, 35.07, 36.21, 52.29, 59.42, 63.64, 118.38, 121.16, 122.00, 125.12, 126.55, 128.39, 129.59, 132.28, 133.85, 137.62, 138.83, 140.91, 142.92, 147.53, 148.86, 151.63, 166.17, 170.95 ppm; UV-vis (CH₂Cl₂): λ_{max} (log ε)= 420 (5.30), 514 (4.53), 545 (4.48), 577 (4.53), 652 (4.51); HRMS (ES+) [C₇₆H₇₃N₆O₈]: calcd for [M+H]⁺ 1197.5490, found 1197.5450.

4.5.12 5-Hexyl-15-(2-*o*-nitrobenzylcarboxyethenyl)-10,20-diphenylporphyrin (41). 5-(2-Carboxyethenyl)-15-hexyl-10,20-diphenylporphyrin **25** (0.01 g, 0.02 mmol), EDAC (6.21 mg, 0.03 mmol), DMAP (3.95 mg, 0.03 mmol) and 2-nitrobenzylalcohol (10.05 mg, 0.06 mmol) were stirred for 18 h in DCM (10 mL) according to method B (4.5.6). Purification on silica gel (*n*-hexane/dichloromethane = 1:2, v/v) yielded **41** as a purple solid (9.88 mg, 0.01 mmol, 81%); mp >310 °C; R_f =0.53 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ=−2.39 (s, 2H, NH), 0.88 (t, *J*=7.3 Hz, 3H, -CH₃), 1.35–1.38 (m, 2H, -CH₂), 1.46–1.49 (m, 2H, -CH₂), 1.73–1.79 (m, 2H, -CH₂), 2.45–2.53 (m, 2H, -CH₂), 4.93 (t, *J*=7.6 Hz, 2H, -CH₂), 5.88 (s, 2H, -OCH₂), 6.86 (d, *J*=15.8 Hz, 1H, -CH=), 7.53 (t, *J*=8.2 Hz, 2H, phenyl-*H*), 7.70 (d, *J*=7.6 Hz, 1H, phenyl-*H*), 7.77 (m, 6H, phenyl-*H*), 7.83 (d, *J*=7.6 Hz, 1H, phenyl-*H*), 8.16 (dd, *J*₁=7.6 Hz, *J*₂=7.0 Hz, 4H, phenyl-*H*), 8.84 (dd, *J*₁=4.7 Hz, *J*₂=4.7 Hz, 4H, β-*H*), 9.41 (t, *J*=4.7 Hz, 4H, β-*H*), 10.27 (d, *J*=15.8 Hz, 1H, =CH-); ¹³C NMR (100 MHz, CDCl₃): δ=13.71, 22.27, 29.27, 29.81, 31.43, 35.07, 38.38, 62.09, 62.89, 120.33, 122.62, 124.56, 126.29, 127.45, 128.04, 128.70, 129.50, 133.97, 136.32, 141.65, 146.65 ppm; UV-vis (CH₂Cl₂): λ_{max} (log ε)= 427 (5.46), 526 (4.62), 572 (4.66), 599 (4.56), 653 (4.56); HRMS (ES+) [C₄₈H₄₂N₅O₄]: calcd for [M+H]⁺ 752.3231, found 752.3237.

4.5.13 5-Hexyl-10,20-bis(3-methoxyphenyl)-15-(2-*o*-nitrobenzylcarboxyethenyl)porphyrin (42). 5-(2-Carboxyethenyl)-15-hexyl-10,20-bis(3-methoxyphenyl)porphyrin **26** (0.02 g, 0.03 mmol), EDAC (10.54 mg, 0.05 mmol), DMAP (6.71 mg, 0.05 mmol) and 2-nitrobenzylalcohol (17.06 mg, 0.10 mmol) were stirred for 18 h in DCM (10 mL) according to method B (4.5.6). Purification on silica gel (*n*-hexane/dichloromethane = 1:2, v/v) yielded **42** as a purple solid (19.67 mg, 0.02 mmol, 83%); mp >310 °C; R_f =0.36 (SiO₂, EtOAc/C₆H₁₄, 1:3, v/v); ¹H NMR (400 MHz, CDCl₃, TMS): δ=−2.41 (s, 2H, NH), 0.90 (t, *J*=7.3 Hz, 3H, -CH₃), 1.33–1.39 (m, 2H, -CH₂), 1.46–1.50 (m, 2H, -CH₂), 1.74–1.82 (m, 2H, -CH₂), 2.46–

2.54 (m, 2H, $-CH_2$), 4.13 (t, $J=7.6$ Hz, 2H, $-CH_2$), 4.94 (s, 6H, $-OCH_3$), 5.89 (s, 2H, $-OCH_2$), 6.86 (d, $J=15.8$ Hz, 1H, $-CH=$), 7.33 (d, $J=8.4$ Hz, 2H, phenyl- H), 7.45 (t, $J=8.0$ Hz, 2H, phenyl- H), 7.53 (t, $J=7.7$ Hz, 1H, phenyl- H), 7.64 (t, $J=7.7$ Hz, 4H, phenyl- H), 7.83 (d, $J=7.7$ Hz, 1H, phenyl- H), 8.07 (d, $J=8.1$ Hz, 1H, phenyl- H), 8.17 (d, $J=8.0$ Hz, 1H, phenyl- H), 8.88 (dd, $J_1=4.4$ Hz, $J_2=4.4$ Hz, 4H, β - H), 9.41 (s, 4H, β - H), 10.26 (d, $J=15.8$ Hz, 1H, $=CH-$); ^{13}C NMR (100 MHz, $CDCl_3$): $\delta=14.15, 22.70, 28.22, 31.89, 35.50, 38.88, 55.54, 62.59, 110.58, 117.86, 120.43, 126.31, 128.86, 134.15, 143.43, 144.59, 147.96, 165.63, 169.68$ ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ) = 426 (5.26), 527 (3.72), 575 (4.79), 600 (4.75), 652 (4.75); HRMS (ES+) [$C_{50}H_{46}N_5O_4$]: calcd for $[M+H]^+$ 812.3455, found 812.3448.

4.5.14 5,10,15,20-Tetrakis(3,5-di-*tert*-butylphenyl)-2-(4-(*o*-nitrobenzylcarboxy)phenyl)porphyrin (43). 2-(4-carboxyphenyl)-5,10,15,20-tetrakis(3,5-di-*tert*-butylphenyl)porphyrin **24** (0.01 g, 0.01 mmol), EDAC (3.24 mg, 0.02 mmol), DMAP (2.06 mg, 0.02 mmol) and 2-nitrobenzylalcohol (5.24 mg, 0.03 mmol) were stirred for 18 h in DCM (10 mL) according to method B (4.5.6). Purification on silica gel (*n*-hexane/dichloromethane = 1:1, v/v) yielded **43** as a purple solid (7.57 mg, 0.01 mmol, 68%): mp >310 °C; $R_f=0.82$ (SiO_2 , EtOAc/ C_6H_{14} , 1:3, v/v); ^1H NMR (400 MHz, $CDCl_3$, TMS): $\delta=-2.56$ (s, 2H, $-NH$), 1.50 (s, 72H, $-C(CH_3)_3$), 5.81 (s, 2H, $-OCH_2$), 7.34 (t, $J=1.8$ Hz, 1H, phenyl- H), 7.50 (d, $J=8.0$ Hz, 1H, phenyl- H), 7.68-7.70 (m, 4H, phenyl- H), 7.75-7.78 (m, 4H, phenyl- H), 7.82 (d, $J=1.8$ Hz, 2H, phenyl- H), 7.85 (d, $J=8.4$ Hz, 1H, phenyl- H), 8.06 (dd, $J_1=1.8$ Hz, $J_2=1.8$ Hz, 4H, phenyl- H), 8.12 (d, $J=1.8$ Hz, 2H, phenyl- H), 8.18 (d, $J=8.1$ Hz, 1H, phenyl- H), 8.71 (d, $J=4.8$ Hz, 1H, β - H), 8.74 (s, 1H, β - H), 8.82 (m, 1H, β - H), 8.85 (d, $J=3.6$ Hz, 2H, β - H), 8.90 (m, 2H, β - H); ^{13}C NMR (100 MHz, $CDCl_3$): $\delta=14.20, 23.91, 29.43, 30.05, 32.76, 34.88, 37.11, 121.01, 128.70, 129.60, 130.04, 130.68, 133.80, 139.99, 147.99, 148.64, 148.82, 165.90$ ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ) = 426 (5.23), 525 (4.23), 576 (4.30), 601 (4.28), 653 (4.33); HRMS (ES+) [$C_{90}H_{104}N_5O_4$]: calcd for $[M+H]^+$ 1318.8090, found 1318.8030.

4.6 Synthesis of porphyrin bioconjugates

4.6.1 5,10,15-Tris(3,5-di-*tert*-butylphenyl)-20-(4'-(*o*-nitro-*p*-(2',3',4',6'-tetra-*O*-acetyl- β -D-galactopyranoside)benzylcarboxy)phenyl)-porphyrin (44). 5-(Carboxyphenyl)-10,15,20-tris(3,5-di-*tert*-butylphenyl)porphyrin **29** (0.08 g, 0.08 mmol), EDAC (30.8 mg, 0.16 mmol), DMAP (19.6 mg, 0.16 mmol) and 5-(acetoglucose)-2-nitrophenylmethanol (0.16 g, 0.32 mmol) were stirred for 18 h in DCM (15 mL). The solution was diluted with DCM and extracted with a solution of aqueous NH_4Cl . The mixture was washed with brine and dried over Na_2SO_4 , followed by evaporation of the solvent to give the crude product. Purification on silica gel (*n*-hexane/dichloromethane = 1:1, v/v) yielded **44** as a purple solid

(90.3 mg, 0.02 mmol, 76%): mp >310 °C; $R_f=0.32$ (SiO_2 , EtOAc/ C_6H_{14} , 1:3, v/v); ^1H NMR (400 MHz, $CDCl_3$, TMS): $\delta=-2.71$ (s, 2H, NH), 1.52 (s, 54H, $-C(CH_3)_3$), 1.83 (s, 3H, $-COCH_3$), 1.99 (s, 3H, $-COCH_3$), 2.06 (s, 6H, $-COCH_3$), 3.90-3.93 (m, 1H, $-CH$), 4.16 (d, $J=10.5$ Hz, 1H, $-CH$), 4.28 (dd, $J_1=5.0$ Hz, $J_2=5.0$ Hz, 1H, $-CH$), 5.15-5.20 (m, 1H, $-CH$), 5.30-5.33 (m, 3H, $-CH$ and $-CH_2CO$), 5.97 (s, 2H, $-OCH_2$), 7.10 (dd, $J_1=2.2$ Hz, $J_2=2.2$ Hz, 1H, phenyl- H), 7.42 (d, $J=2.28$ Hz, 1H, phenyl- H), 7.79 (s, 3H, phenyl- H), 8.07 (s, 6H, phenyl- H), 8.27 (d, $J=9.0$ Hz, 1H, phenyl- H), 8.38 (d, $J=8.0$ Hz, 2H, phenyl- H), 8.49 (d, $J=8.0$ Hz, 2H, phenyl- H), 8.79 (d, $J=4.5$ Hz, 2H, β - H), 8.91 (s, 6H, β - H); ^{13}C NMR (100 MHz, $CDCl_3$): $\delta=31.77, 35.08, 61.70, 63.74, 67.83, 70.94, 72.44, 98.08, 115.68, 116.81, 117.64, 121.10, 121.70, 122.05, 128.07, 128.61, 129.83, 134.83, 135.68, 141.14, 142.42, 148.25, 160.48, 169.23, 170.11, 170.43$ ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ) = 421 (5.18), 518 (3.81), 553 (3.60), 593 (3.41), 667 (3.75); HRMS (ES+) [$C_{90}H_{102}N_5O_{14}$]: calcd for $[M+H]^+$ 1476.7420, found 1476.7410.

4.7 Protecting group approach

4.7.1 5-(Methoxyethoxymethyl)-2-nitrophenylmethanol (46). 5-(Methoxyethoxymethyl)-2-nitrobenzaldehyde²⁸ **45** (0.62 g, 2.44 mmol) was dissolved in THF (50 mL) and the solution was cooled to 0 °C. Sodium borohydride (92 mg, 2.44 mmol) was added and the mixture was stirred for 2 hours. The mixture was filtered through silica gel and the solvent was evaporated *in vacuo* to yield the title compound **46** as a yellow solid (0.62 g, 0.16 mmol, 98%): mp 98-101 °C; $R_f=0.29$ (SiO_2 , EtOAc/ C_6H_{14} , 1:3, v/v); ^1H NMR (400 MHz, $CDCl_3$, TMS): $\delta=3.22$ (s, 3H, $-OCH_3$), 3.22-3.46 (m, 2H, $-CH_2O$), 3.71-3.41 (m, 2H, $-OCH_2$), 4.11 (br. s, 1H, $-OH$), 4.84 (s, 2H, $-CH_2OH$), 5.24 (s, 2H, $-OCH_2O$), 6.88 (dd, $J_1=2.4$ Hz, $J_2=2.3$ Hz, 1H, phenyl- H), 7.30 (s, 1H, phenyl- H), 7.95 (d, $J=9.36$ Hz, 1H, phenyl- H); ^{13}C NMR (100 MHz, $CDCl_3$): $\delta=58.27, 61.34, 67.57, 70.89, 92.61, 113.78, 114.57, 127.00, 139.81, 140.69, 161.16$ ppm; HRMS (ES+) [$C_{11}H_{15}NO_6$]: calcd for $[M+Na]^+$ 280.0797, found 280.0800.

4.7.2 5-Hexyl-15-(4-(*o*-nitro-*p*-methoxyethoxymethylbenzylcarboxy)phenyl)-10,20-diphenylporphyrin (47). 5-(4-Carboxyphenyl)-15-hexyl-10,20-diphenylporphyrin **18** (0.05 g, 0.08 mmol), EDAC (28.8 mg, 0.15 mmol), DMAP (18.3 mg, 0.15 mmol) and 5-(methoxyethoxymethyl)-2-nitrophenylmethanol **46** (77.2 mg, 0.30 mmol) were stirred for 18 h in DCM (10 mL). The solution was diluted with DCM and extracted with a solution of aqueous NH_4Cl . The mixture was washed with brine and dried over Na_2SO_4 , followed by evaporation of the solvent to give the crude product. Purification on silica gel (*n*-hexane/dichloromethane = 1:2, v/v) yielded **47** as a purple solid (19.67 mg, 0.02 mmol, 83%): mp >310 °C; $R_f=0.36$ (SiO_2 , EtOAc/ C_6H_{14} , 1:3, v/v); ^1H NMR (400 MHz, $CDCl_3$, TMS): $\delta=-2.72$ (s, 2H, NH), 0.93 (t, $J=6.8$ Hz, 3H, $-CH_3$), 1.36-1.41 (m, 2H, $-CH_2$), 1.47-1.54 (m, 2H, $-CH_2$), 1.76-

1.83 (m, 2H, $-CH_2$), 2.50-2.58 (m, 2H, $-CH_2$), 3.31 (s, 3H, $-OCH_3$), 3.53 (t, $J=3.9$ Hz, 2H, $-OCH_2$), 3.82 (t, $J=3.9$ Hz, 2H, $-CH_2OCH_3$), 4.96 (t, $J=8.8$ Hz, 2H, $-CH_2$), 5.34 (s, 2H, $-OCH_2$), 5.92 (s, 2H, $-OCH_2O$), 7.09 (dd, $J_1=2.0$ Hz, $J_2=2.0$ Hz, 1H, phenyl- H), 7.43 (d, $J=1.96$ Hz, 1H, phenyl- H), 7.74-7.80 (m, 6H, phenyl- H), 8.20 (s, 1H, phenyl- H), 8.22 (d, $J=5.8$ Hz, 4H, phenyl- H), 8.33 (d, $J=7.8$ Hz, 2H, phenyl- H), 8.49 (d, $J=7.8$ Hz, 2H, phenyl- H), 8.77 (d, $J=4.9$ Hz, 2H, β - H), 8.84 (d, $J=4.9$ Hz, 2H, β - H), 8.92 (d, $J=4.9$ Hz, 2H, β - H), 9.46 (d, $J=4.9$ Hz, 2H, β - H); ^{13}C NMR (100 MHz, $CDCl_3$): $\delta=13.73$, 22.29, 29.28, 29.83, 31.47, 35.17, 38.50, 58.64, 62.14, 62.70, 63.42, 67.88, 71.02, 93.03, 114.35, 115.67, 117.07, 119.40, 120.90, 126.23, 127.32, 127.71, 128.45, 134.04, 140.65, 141.83, 147.08, 159.69, 161.23, 165.68, 169.89 ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ)= 418 (5.16), 516 (3.90), 551 (3.65), 594 (3.58), 653 (3.78); HRMS (ES+) [$C_{56}H_{52}N_5O_7$]: calcd for $[M+H]^+$ 906.3867, found 906.3899.

4.7.3 5-Hexyl-15-(hydroxyethylcarboxyphenyl)-10,20-diphenylporphyrin (48). 5-Hexyl-15-(4'- o -nitro- p -(methoxyethoxymethyl)benzylcarboxy)phenyl)-10,20-diphenylporphyrin **47** (0.05 g, 0.06 mmol) was dissolved in a small amount of THF. Ethylene glycol (10 mL) was added to the solution and was heated at 140 °C for 5 hours (TLC monitor). The reaction was cooled to room temperature and was washed with saturated aqueous sodium bicarbonate and brine. The solution was dried over anhydrous magnesium sulfate and the solvent evaporated under reduced pressure to yield **48** as a purple solid (64.7 mg, 0.05 mmol, 92%): mp >310 °C; $R_f=0.44$ (SiO_2 , EtOAc/ C_6H_{14} , 1:3, v/v); ^1H NMR (400 MHz, $CDCl_3$, TMS): $\delta=-2.75$ (s, 2H, NH), 0.91 (t, $J=7.0$ Hz, 3H, $-CH_3$), 1.34-1.40 (m, 2H, $-CH_2$), 1.46-1.53 (m, 2H, $-CH_2$), 1.76-1.83 (m, 2H, $-CH_2$), 2.49-2.55 (m, 2H, $-CH_2$), 4.09 (s, 2H, $-OCH_2$), 4.64 (t, $J=4.0$ Hz, 2H, $-CH_2OH$), 5.00 (t, $J=8.2$ Hz, 2H, $-CH_2$), 7.72-7.80 (m, 6H, phenyl- H), 8.18 (d, $J=6.4$ Hz, 4H, phenyl- H), 8.27 (d, $J=8.2$ Hz, 2H, phenyl- H), 8.43 (d, $J=8.2$ Hz, 2H, phenyl- H), 8.71 (d, $J=5.3$ Hz, 2H, β - H), 8.79 (d, $J=4.7$ Hz, 2H, β - H), 8.90 (d, $J=5.2$ Hz, 2H, β - H), 9.47 (d, $J=4.7$ Hz, 2H, β - H); ^{13}C NMR (100 MHz, $CDCl_3$): $\delta=14.17$, 22.74, 30.29, 31.94, 35.64, 38.95, 61.63, 66.98, 93.50, 114.94, 116.54, 117.59, 119.83, 121.33, 127.87, 128.92, 134.78, 142.30, 147.34, 167.24 ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ)= 418 (5.17), 517 (2.30), 551 (3.45), 594 (3.28), 650 (3.38); HRMS (ES+) [$C_{47}H_{43}N_4O_3$]: calcd for $[M+H]^+$ 711.3335, found 711.3354.

4.7.4 [5-(4-(Ethoxycarbonylphenyl))-15-hexyl-10,20-diphenylporphyrin]-carboxyethenyl)-10,15,20-triphenylporphyrinato]nickel(II) (50). 5-(2-Carboxyethenyl)-10,15,20-triphenylporphyrinato]nickel(II)^{21d} **49** (0.01 g, 0.02 mmol), EDAC (2.88 mg, 0.03 mmol), DMAP (1.83 mg, 0.03 mmol) and 5-hexyl-15-(hydroxyethylcarboxyphenyl)-10,20-diphenylporphyrin **48** (11 mg, 0.02 mmol) were stirred for 18 h in DCM (10 mL). The solution was diluted with DCM and extracted with a solution of aqueous NH_4Cl . The mixture was washed with

brine and dried over Na_2SO_4 , followed by evaporation of the solvent to give the crude product. Purification on silica gel (n -hexane/dichloromethane = 1:2, v/v) yielded the title compound as a purple solid (19.0 mg, 0.03 mmol, 93%): mp >310 °C; $R_f=0.15$ (SiO_2 , EtOAc/ C_6H_{14} , 1:3, v/v); ^1H NMR (400 MHz, $CDCl_3$, TMS): $\delta=-2.78$ (s, 2H, NH), 0.97 (t, $J=7.3$ Hz, 3H, $-CH_3$), 1.63-1.65 (m, 2H, $-CH_2$), 1.74-1.79 (m, 2H, $-CH_2$), 1.94-1.97 (m, 2H, $-CH_2$), 2.51-2.55 (m, 2H, $-CH_2$), 4.52-4.56 (m, 4H, $-CH_2$), 5.00 (t, $J=7.6$ Hz, 2H, $-CH_2$), 6.41 (d, $J=15.2$ Hz, 1H, $-CH=C$), 7.50-7.52 (m, 6H, phenyl- H), 7.68-7.77 (m, 9H, phenyl- H), 7.86 (d, $J=7.0$ Hz, 4H, phenyl- H), 7.91 (d, $J=8.2$ Hz, 2H, phenyl- H), 8.13 (d, $J=6.44$ Hz, 4H, phenyl- H), 8.25 (d, $J=8.2$ Hz, 2H, phenyl- H), 8.48 (d, $J=8.2$ Hz, 2H, phenyl- H), 8.57 (d, $J=4.7$ Hz, 2H, β - H), 8.63 (d, $J=4.7$ Hz, 2H, β - H), 8.66 (d, $J=4.7$ Hz, 2H, β - H), 8.69 (d, $J=4.7$ Hz, 2H, β - H), 8.77 (d, $J=5.2$ Hz, 2H, β - H), 8.87 (d, $J=4.7$ Hz, 2H, β - H), 9.39 (d, $J=4.7$ Hz, 2H, β - H), 9.46 (d, $J=4.7$ Hz, 2H, β - H), 9.98 (d, $J=15.8$ Hz, 1H, $=CHCO$); ^{13}C NMR (100 MHz, $CDCl_3$): $\delta=14.18$, 20.76, 22.74, 23.35, 23.79, 25.01, 25.64, 29.11, 29.46, 29.74, 30.29, 31.94, 35.64, 38.94, 62.80, 63.15, 68.01, 73.55, 91.21, 109.33, 117.62, 119.54, 119.79, 120.48, 121.27, 126.62, 126.95, 126.99, 129.15, 130.74, 131.38, 132.32, 132.76, 133.49, 133.52, 134.46, 134.67, 140.16, 141.52, 142.17, 142.83, 144.79, 147.30, 166.15, 166.75 ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ)= 420 (5.11), 523 (4.41), 546 (4.41), 597 (4.40), 653 (4.45); HRMS (ES+) [$C_{88}H_{67}NiN_8O_4$]: calcd for $[M+H]^+$ 1357.4639, found 1357.4669.

4.7.5 [5-Hexyl-15-(3- o -nitro- p -(methoxyethoxymethyl)benzylcarboxyphenyl)-10,20-diphenylporphyrinato]-zinc(II) (51). 5-Hexyl-15-(4- o -nitro- p -(methoxyethoxymethyl)benzylcarboxyphenyl)-10,20-diphenylporphyrin **47** (0.10 g, 0.11 mmol) was dissolved in $CHCl_3$ (30 mL). Two drops of TFA were added, followed by zinc(II)oxide (26.9 mg, 0.33 mmol). The solution was stirred for 18 hours and filtered. The solvent was evaporated and subjected to column chromatography (SiO_2 , n -hexane/dichloromethane = 1:2, v/v) and gave the **51** as a purple solid (100.24 mg, 0.10 mmol, 94%): mp >310 °C; $R_f=0.32$ (SiO_2 , EtOAc/ C_6H_{14} , 1:3, v/v); ^1H NMR (400 MHz, $CDCl_3$, TMS): $\delta=0.93$ (t, $J=7.0$ Hz, 3H, $-CH_3$), 1.38-1.42 (m, 2H, $-CH_2$), 1.46-1.52 (m, 2H, $-CH_2$), 1.76-1.83 (m, 2H, $-CH_2$), 2.50-2.58 (m, 2H, $-CH_2$), 3.15 (s, 3H, $-OCH_3$), 3.35 (t, $J=4.1$ Hz, 2H, $-OCH_2$), 3.39 (t, $J=4.1$ Hz, 2H, $-CH_2OCH_3$), 4.97 (t, $J=8.2$ Hz, 2H, $-CH_2$), 5.24 (s, 2H, $-OCH_2$), 5.85 (s, 2H, $-OCH_2O$), 7.03 (d, $J=2.9$ Hz, 1H, phenyl- H), 7.36 (d, $J=2.4$ Hz, 1H, phenyl- H), 7.72-7.78 (m, 6H, phenyl- H), 8.16 (s, 1H, phenyl- H), 8.18 (d, $J=5.8$ Hz, 4H, phenyl- H), 8.29 (d, $J=7.6$ Hz, 2H, phenyl- H), 8.42 (d, $J=8.2$ Hz, 2H, phenyl- H), 8.82 (d, $J=4.7$ Hz, 2H, β - H), 8.89 (d, $J=4.7$ Hz, 2H, β - H), 8.97 (d, $J=4.6$ Hz, 2H, β - H), 9.53 (d, $J=4.6$ Hz, 2H, β - H); ^{13}C NMR (100 MHz, $CDCl_3$): $\delta=13.74$, 22.31, 29.27, 29.98, 31.49, 35.43, 38.76, 58.48, 62.10, 62.66, 63.32, 67.72, 70.85, 92.88, 114.22, 114.58, 115.31, 118.12, 120.31, 121.78, 127.08, 127.45, 128.18, 128.63, 130.78, 134.17, 135.05, 140.55, 142.36, 147.94, 149.32, 149.74,

159.67, 161.10, 165.70, 169.85 ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ) = 420 (5.23), 549 (3.86), 588 (3.00); HRMS (ES^+) [$\text{C}_{56}\text{H}_{50}\text{N}_5\text{O}_7\text{Zn}$]: calcd for $[\text{M}+\text{H}]^+$ 968.3002, found 968.2964

4.7.6 5-Hexyl-15-(4'-(*o*-nitro-*p*-hydroxybenzyl-carboxy)-phenyl)-10,20-diphenylporphyrin (52). A solution of [5-hexyl-15-(3-*o*-nitro-*p*-(methoxyethoxymethyl)benzyl carboxyphenyl)-10,20-diphenylporphyrinato]zinc(II) **51** (0.06 g, 0.06 mmol) in CH_2Cl_2 (3.30 ml) was treated with trifluoroacetic acid (3.30 ml), stirred at rt for 7 hours and concentrated. The solution was neutralized with aqueous-KOH and extracted with CH_2Cl_2 . The organic phase was dried over Na_2SO_4 , filtered and the solvent was removed under reduced pressure to yield the title compound **52** as a purple solid (34.8 mg, 0.03 mmol, 71%); mp >310 °C; R_f =0.28 (SiO_2 , $\text{EtOAc}/\text{C}_6\text{H}_{14}$, 1:3, v/v); ^1H NMR (400 MHz, CDCl_3 , TMS): δ = -2.62 (s, 2H, NH), 0.93 (t, J =7.0 Hz, 3H, $-\text{CH}_3$), 1.34-1.42 (m, 2H, $-\text{CH}_2$), 1.45-1.53 (m, 2H, $-\text{CH}_2$), 1.75-1.83 (m, 2H, $-\text{CH}_2$), 2.49-2.57 (m, 2H, $-\text{CH}_2$), 4.98 (t, J =7.6 Hz, 2H, $-\text{CH}_2$), 5.86 (s, 2H, $-\text{OCH}_2$), 6.63 (dd, J_1 =2.8 Hz, J_2 =2.5 Hz, 1H, phenyl-*H*), 7.03 (s, 1H, phenyl-*H*), 7.71-7.77 (m, 6H, phenyl-*H*), 8.10 (dd, J_1 =2.0 Hz, J_2 =1.8 Hz, 1H, phenyl-*H*), 8.17-8.19 (m, 4H, phenyl-*H*), 8.26 (d, J =8.2 Hz, 2H, phenyl-*H*), 8.42 (d, J =7.6 Hz, 2H, phenyl-*H*), 8.71 (d, J =4.6 Hz, 2H, β -*H*), 8.79 (d, J =4.7 Hz, 2H, β -*H*), 8.90 (d, J =4.7 Hz, 2H, β -*H*), 9.46 (d, J =4.7 Hz, 2H, β -*H*); ^{13}C NMR (100 MHz, CDCl_3): δ =14.17, 20.78, 22.74, 29.40, 31.96, 35.65, 38.96, 62.58, 114.89, 121.09, 126.69, 127.79, 128.18, 128.39, 129.71, 134.77, 142.27, 148.73, 161.26, 169.54 ppm; UV-vis (CH_2Cl_2): λ_{max} (log ϵ) = 419 (5.45), 517 (4.06), 551 (3.69), 594 (3.56), 650 (3.68); HRMS (ES^+) [$\text{C}_{52}\text{H}_{44}\text{N}_5\text{O}_5$]: calcd for $[\text{M}+\text{H}]^+$ 818.3342, found 818.3313.

4.8 Irradiation Experiment

A 50 μM solution of 5,10,15-Tris(3,5-di-*tert*-butylphenyl)-20-(4'-(*o*-nitro-*p*-(2',3',4',6'-tetra-*O*-acetyl- β -D-galactopyrano-side)benzyl)carboxy)phenyl)-porphyrin **44** in 2% water/ 98% acetone was placed in a quartz cuvette. Irradiation was performed using a photochemical chamber reactor (Rayonet Model RMR-600) with 350 ± 25 nm UV lamps. Aliquots of 20 μL were removed at different time intervals of irradiation and analyzed by analytical HPLC (detection UV: 350 nm) using a nucleosile 5u Si 100A (250 X 4.00 mm) column and eluting with a mixture of *n*-Hexane:Ethyl Acetate (50:50) at a flow rate of 1.5 ml/min.

Acknowledgments

This work was generously supported by a Science Foundation Ireland Research Professorship Award (SFI 04/RP1/B482), the Health Research Board (HRB TRA2007/11), and by the Universiti Teknologi Malaysia.

References

- (a) Dougherty, T. J. *Photochem. Photobiol.* **1993**, *58*, 895–900. (b) Sternberg, E. D.; Dolphin, D.; Brückner, C. *Tetrahedron* **1998**, *54*, 4151–4202. (c) Pandey, R. K. *J. Porphyrins Phthalocyanines* **2000**, *4*, 368–373. (d) Macdonald, I. J.; Dougherty, T. J. *J. Porphyrins Phthalocyanines* **2001**, *5*, 105–129. (e) Nyman, E. S.; Hynninen, P. H. *J. Photochem. Photobiol. B: Biol.* **2004**, *73*, 1–28.
- (a) Biel, M. A. *J. Clin. Laser Med. Surg.* **1996**, *14*, 239–244. (b) Ris, H. B.; Altermatt, H. J.; Nachbur, B. *Lasers Surg. Med.* **1996**, *18*, 39–45. (c) Moskal, T. L.; Dougherty, T. J.; Urschel, J. D.; Antkowiak, J. G.; Regal, A. M.; Driscoll, D. L.; Takita, H. *Ann. Thorac. Surg.* **1998**, *66*, 1128–1133. (d) Weersink, A.; Bogaards, A.; Gertner, M.; Davidson, S. R.; Zhang, K.; Natchev, G.; Trachtenberg, J.; Wilson, B. C. *J. Photochem. Photobiol. B: Biol.* **2005**, *79*, 211–222. (e) Bogaards, A.; Varma, A.; Zhang, K.; Zach, D.; Bisland, S. K.; Moriyama, E. H.; Lilge, L.; Muller, P. J.; Wilson, B. C. *Photochem. Photobiol. Sci.* **2005**, *4*, 438–442.
- Moan, J.; Berg, K. *Photochem. Photobiol.* **1991**, *53*, 549–553.
- (a) Boyle, R. W.; Dolphin, D. *Photochem. Photobiol.* **1996**, *64*, 469–485. (b) Ben-Dror, S.; Bronshtein, I.; Wiehe, A.; Röder, B.; Senge, M. O.; Ehrenberg, B. *Photochem. Photobiol.* **2006**, *82*, 695–701. Wiehe, A.; Simonenko, E. J.; Senge, M. O.; Röder, B. *J. Porphyrins Phthalocyanines* **2001**, *5*, 758–761.
- (a) van Nostrum, C. F. *Adv. Drug Deliv. Rev.* **2004**, *56*, 9–16. (b) Cinteza, L. O.; Ohulchanskyy, T. Y.; Sahoo, Y.; Bergey, E. J.; Pandey, R. K.; Prasad, P. N. *Mol. Pharm.* **2006**, *3*, 415–423. (c) Liu, J.; Ohta, S. I.; Sonoda, A.; Yamada, M.; Yamamoto, M.; Nitta, N.; Murata, K.; Tabata, Y. *J. Control. Release* **2007**, *117*, 104–110. (d) Simioni, A. R.; Vaccari, C.; Re, M. I.; Tedesco, A. C. *J. Mat. Sci.* **2008**, *43*, 580–584.
- (a) Bachor, R.; Shea, C. R.; Gillies, R.; Hasan, T. *Proc. Natl Acad. Sci. USA* **1991**, *88*, 1580–1584. (b) Allemann, E.; Rousseau, J.; Brasseur, N.; Kudrevich, S. V.; Lewis, K.; van Lier, J. E. *Int. J. Cancer* **1996**, *66*, 821–824. (c) Oba, T. *Curr. Bio. Comp.* **2007**, *3*, 239–251. (d) Baba, K.; Pudavar, H. E.; Roy, I.; Ohulchanskyy, T. Y.; Chen, Y.; Pandey, R. K.; Prasad, P. N. *Mol. Pharm.* **2007**, *4*, 289–297.
- (a) Rosenkranz, A. A.; Jans, D. A.; Sobolev, A. S. *Imm. Cell Bio.* **2000**, *78*, 452–464. (b) Hamblin, M. *Photochem. Photobiol.* **2000**, *72*, 533–540. (c) Sharmman, W. M.; van Lier, J. E.; Allen, C. M. *Adv. Drug Deliv. Rev.* **2004**, *56*, 53–76.
- Gamblin, D. P.; Scanlan, E. M.; Davis, B. G. *Chem. Rev.* **2009**, *109*, 131–163.
- (a) Reinhard, R.; Schmidt, B. F. *J. Org. Chem.* **1998**, *63*, 2434–2441. (b) McCoy, C. P.; Rooney, C.; Jones, D. S.; Gorman, S. P.; Nieuwenhuysen, M. *Pharm. Res.* **2007**, *24*, 194–200. (c) Saito, I.; Okamoto, A.; Tanabe, K.; Inasaki, T. *Angew. Chem. Int. Ed.* **2003**, *42*, 2502–2504. (d) McCoy, C. P.; Rooney, C.; Edwards, C. R.; Jones, D. S.; Gorman, S. P. *J. Am. Chem. Soc.* **2007**, *129*, 9572–9572. (e) Hampp, N.; Hartner, S.; Kim, H. C. *J. Polym. Sci. Part A: Polym.* **2007**, *45*, 2443–2452.
- (a) Schwartz, T. *J. Photochem. Photobiol. B: Biol.* **1998**, *44*, 91–96. (b) Aragane, Y.; Kulms, D.; Metz, D.; Wilkes, G.; Pöppelmann, B.; Luger, T. A.; Schwarz, T. *J. Cell. Bio.* **1998**, *140*, 171–182. (c) Leverkus, M.; Yaar, M.; Gilchrist, B. A.; Exp. Cell Res. **1997**, *232*, 255–262. (d) Dunkern, T. R.; Fritz, G.; Kaina, B. *Oncogene* **2001**, *20*, 6026–6038.
- Senge, M. O.; Hatscher, S. S.; Wiehe, A.; Dahms, K.; Kelling, A. *J. Am. Chem. Soc.* **2004**, *126*, 13634–13635. Dahms, K.; Senge, M. O.; Bakar, M. B. *Eur. J. Org. Chem.* **2007**, 3833–3848.

12. Lin, W.; Peng, D.; Wang, B.; Long, L.; Guo, C.; Yuan, J. *Eur. J. Org. Chem.* **2008**, 793–796.
13. (a) Bochet, C. G. *J. Chem. Soc., Perkin Trans. 1* **2002**, 125–142. (b) Aujard, I.; Benbrahim, C.; Gouget, M.; Ruel, O.; Baudin, J.-B.; Neveu, P.; Jullien, L. *Chem. Eur. J.* **2006**, *12*, 6865–6879.
14. (a) Baolu, S.; Boyle, R. W. *J. Chem. Soc., Perkin Trans. 1* **2002**, 1397–1400. (b) Chan, K. S.; Zhou, X.; Luo, B.-S.; Mak, T. C. W. *J. Chem. Soc., Chem. Comm.* **1994**, 271–272. (c) Chan, K. S.; Zhou, X.; Au, M. T.; Tam, C. Y. *Tetrahedron* **1995**, *51*, 3129–3136.
15. (a) Shanmugathan, S.; Johnson, C. K.; Edwards, C.; Matthews, E. K.; Dolphin, D.; Boyle, R. W. *J. Porphyrins Phthalocyanines* **2000**, *4*, 228–232. (b) Locos, O. B.; Arnold, D. P. *Org. Biomol. Chem.* **2006**, *4*, 902–916. (c) Smith, K. M.; Langry, K. C.; Minnetian, O. M. *J. Org. Chem.* **1984**, *49*, 4602–4609. (d) Tremblay-Morin, J.-P.; Ali, H.; van Lier, J. E. *Tetrahedron Lett.* **2006**, *47*, 3043–3046.
16. Callot, H. J. *Tetrahedron Lett.* **1973**, *50*, 4890–4987.
17. (a) Dolphin, D.; Brückner, C.; Posakony, J. J.; Johnson, C. K.; Boyle, R. W.; James, B. R. *J. Porphyrins Phthalocyanines* **1998**, *2*, 455–465. (b) Lindsey, J. S.; Rao, P. D.; Dhanalekshmi, S.; Littler, B. J. *J. Org. Chem.* **2000**, *65*, 7323–7344.
18. (a) Senge, M. O.; Kalisch, W. W.; Bischoff, I. *Chem. Eur. J.* **2000**, *6*, 2721–2738. (b) Feng, X.; Bischoff, I.; Senge, M. O. *J. Org. Chem.* **2001**, *66*, 8693–8700. (c) Wiehe, A.; Ryppa, C.; Senge, M. O. *Org. Lett.* **2002**, *4*, 3807–3809. Hatscher, S.; Senge, M. O. *Tetrahedron Lett.* **2002**, *58*, 4375–4381. (d) Wiehe, A.; Shaker, Y. M.; Brandt, J. C.; Mebs, S.; Senge, M. O. *Tetrahedron* **2005**, *61*, 5535–5564. (e) Senge, M. O. *Acc. Chem. Res.* **2005**, *38*, 733–743. (f) Senge, M. O.; Feng, X. D. *J. Chem. Soc., Perkin Trans. 1* **2000**, 3615–3621. Feng, X. D.; Senge, M. O. *J. Chem. Soc., Perkin Trans. 1* **2001**, 1030–1038.
19. a) Matile, S.; Berova, N.; Nakanishi, K. *J. Am. Chem. Soc.* **1995**, *117*, 7021–7022. b) Luo, C.; Guldi, D. M.; Imahori, H.; Tamaki, K.; Sakata, Y. *J. Am. Chem. Soc.* **2000**, *122*, 6535–6551.
20. Clarke, O. J.; Boyle, R. W. *Tetrahedron Lett.* **1998**, *39*, 7167–7168.
21. (a) Monti, D.; Venanzi, M.; Russo, M.; Bussetti, G.; Goletti, C.; Montalti, M.; Zaccaroni, N.; Prodi, L.; Rella, R.; Manera, M. G.; Mancini, G.; Di Natale, C.; Paolesse, R. *New J. Chem.* **2004**, *28*, 1123–1128. (b) Stefanelli, M.; Monti, D.; Venanzi, M.; Paolesse, R. *New J. Chem.* **2007**, *31*, 1722–1725. (c) Paolesse, R.; Monti, D.; La Monica, L.; Venanzi, M.; Froio, A.; Nardis, S.; Di Natale, C.; Martinelli, E.; D'Amico, A. *Chem. Eur. J.* **2002**, *8*, 2476–2483. (d) Sergeeva, N. N.; Bakar, M. B.; Senge, M. O. *J. Org. Chem.* **2009**, *74*, 1488–1497.
22. (a) MacMahon, S.; Fong II, R.; Baran, P. S.; Safonov, I.; Wilson, S. R.; Schuster, D. I. *J. Org. Chem.* **2001**, *66*, 5449–5455. (b) MacMillan, J. B.; Molinsk, T. F. *J. Am. Chem. Soc.* **2004**, *126*, 9944–9945. (c) Proni, G.; Pescitelli, G.; Huang, X.; Nakanishi, K.; Berova, N. *J. Am. Chem. Soc.* **2003**, *125*, 12914–12927. (d) Schuster, D. I.; MacMahon, S.; Guldi, D. M.; Echegoyenc, L.; Braslavsky, S. E. *Tetrahedron* **2006**, *62*, 1928–1936. (e) Tsubaki, K.; Takaishi, K.; Tanaka, H.; Miura, M.; Kawabata, T. *Org. Lett.* **2006**, *8*, 2587–2590.
23. Nagvekar, D. S.; Delaviz, Y.; Prasad, A.; Merola, J. S.; Marand, H.; Gibson, H. W. *J. Org. Chem.* **1996**, *61*, 1211–1218.
24. Mathews, B. T.; Beezer, A. E.; Snowden, M. J.; Hardy, M. J.; Mitchell, J. C. *New J. Chem.* **2001**, *25*, 807–818.
25. (a) Casiraghi, G.; Cornia, M.; Zanard, F.; Rassu, G.; Ragg, E.; Bortolini, R. *J. Org. Chem.* **1994**, *59*, 1801–1808. (b) Hombrecher, H. K.; Ohm, S.; Koll, D.; *Tetrahedron* **1996**, *52*, 5441–5448. (c) Schell, C.; Hombrecher, H. K. *Chem. Eur. J.* **1999**, *5*, 587–598. (d) Zheng, G.; Graham, A.; Shibata, M.; Missert, J. R.; Oseroff, A. R.; Dougherty, T. J.; Pandey, R. K. *J. Org. Chem.* **2001**, *66*, 8709–8716.
26. (a) Chen, X.; Hui, L.; Foster, D. A.; Drain, C. M. *Biochemistry* **2004**, *43*, 10918–10929. (b) Dwek, R. A. *Chem. Rev.* **1996**, *96*, 683–720. (c) Sharon, M.; Lis, H. *Science* **246**, 227–234.
27. Kröger, L.; Thiem, J. *Carbohydrate Res.* **2007**, *342*, 467–481.
28. (a) Couve-Bonnaire, S.; Chou, D. T. H.; Gan, Z.; Arya, P. *J. Comb. Chem.* **2004**, *6*, 73–77. (b) Scelhaas, M.; Waldmann, H. *Angew. Chem. Int. Ed.* **2003**, *35*, 2056–2083.
29. Miyake, H.; Tsumura, T.; Sasaki, M. *Tetrahedron Lett.* **2004**, *45*, 7213–7215.
30. Sunazuka, T.; Hirose, T.; Harigaya, Y.; Takamatsu, S.; Hayashi, M.; Komiyama, K.; Omura, S.; Sprengeler, P. A.; Smith III, A. B. *J. Am. Chem. Soc.* **1997**, *119*, 10247–10248.
31. (a) Sudimack, J.; Lee, R. J. *Adv. Drug. Deliv. Rev.* **2000**, *41*, 147–162. (b) Gravier, J.; Schneider, R.; Frochot, C.; Bastogne, T.; Schmitt, F.; Didelon, J.; Guillemin, F.; Barberi-Heyob, M. *J. Med. Chem.* **2008**, *51*, 3867–3877.
32. Yip, R. W.; Sharma, D. K.; Giasson, R.; Gravel, D. *J. Phys. Chem.* **1985**, *89*, 5328–5330.
33. (a) Patchnornik, A.; Amit, B.; Woodward, R. B. *J. Am. Chem. Soc.* **1970**, *92*, 6333–6335. (b) Wirz, J.; Pelliccioli, A. P. *Photochem. Photobiol. Sci.* **2002**, *1*, 441–458.
34. Wenbo, E.; Kadish, K. M.; Santic, P. J.; Khoury, T.; Govenlock, L. J.; Ou, Z.; Shao, J.; Ohkubo, K.; Reimers, J. R.; Fukuzumi, S.; Crossley, M. J. *J. Phys. Chem. A*, **2008**, *112*, 556–570.